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ABSTRACT OF DISSERTATION

STATISTICAL ANALYSES TO DETECT AND REFINE GENETIC ASSOCIATIONS
WITH NEURODEGENERATIVE DISEASES
Dementia is a clinical state caused by neurodegeneration and characterized by a
loss of function in cognitive domains and behavior. Alzheimer’s disease (AD) is the most
common form of dementia. Although the amyloid β (Aβ) protein and
hyperphosphorylated tau aggregates in the brain are considered to be the key pathological
hallmarks of AD, the exact cause of AD is yet to be identified. In addition, clinical
diagnoses of AD can be error prone. Many previous studies have compared the clinical
diagnosis of AD against the gold standard of autopsy confirmation and shown substantial
AD misdiagnosis Hippocampal sclerosis of aging (HS-Aging) is one type of dementia
that is often clinically misdiagnosed as AD. AD and HS-Aging are controlled by different
genetic architectures. Familial AD, which often occurs early in life, is linked to mainly
mutations in three genes: APP, PSEN1, and PSEN2. Late-onset AD (LOAD) is strongly
associated with the ε4 allele of apolipoprotein E (APOE) gene. In addition to the APOE
gene, genome-wide association studies (GWAS) have identified several single nucleotide
polymorphisms (SNPs) in or close to some genes associated with LOAD. On the other
hand, GRN, TMEM106B, ABCC9, and KCNMB2 have been reported to harbor risk alleles
associated with HS-Aging pathology. Although GWAS have succeeded in revealing
numerous susceptibility variants for dementias, it is an ongoing challenge to identify
functional loci and to understand how they contribute to dementia pathogenesis.
Until recently, rare variants were not investigated comprehensively. GWAS rely
on genotype imputation which is not reliable for rare variants. Therefore, imputed rare
variants are typically removed from GWAS analysis. Recent advances in sequencing
technologies enable accurate genotyping of rare variants, thus potentially improving our
understanding the role of rare variants on disease. There are significant computational
and statistical challenges for these sequencing studies. Traditional single variant-based
association tests are underpowered to detect rare variant associations. Instead, more
powerful and computationally efficient approaches for aggregating the effects of rare
variants have become a standard approach for association testing. The sequence-kernel
association test (SKAT) is one of the most powerful rare variant analysis methods. A
recently-proposed scan-statistic-based test is another approach to detect the location of
rare variant clusters influencing disease.

In the first study, we examined the gene-based associations of the four putative
risk genes, GRN, TMEM106B, ABCC9, and KCNMB2 with HS-aging pathology. We
analyzed haplotype associations of a targeted ABCC9 region with HS-Aging pathology
and with ABCC9 gene expression. In the second study, we elucidated the role of the noncoding SNPs identified in the International Genomics of Alzheimer’s Project (IGAP)
consortium GWAS within a systems genetics framework to understand the flow of
biological information underlying AD. In the last study, we identified genetic regions
which contain rare variants associated with AD using a scan-statistic-based approach.
KEYWORDS: Alzheimer’s Disease, Hippocampal Sclerosis of Aging,
Region-based Associations, Rare Variant Associations,
Systems Genetics
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CHAPTER ONE
Introduction
Dementia is a clinical state caused by neurodegeneration and characterized by a loss of
function in cognitive domains and undesirable changes in behavior. Alzheimer’s disease
(AD) is the most common form of dementia, accounting for over 50% of dementia cases
[1]. In the US, it has been estimated that 5.2 million people have AD and total payments
from health-care and long-care services for AD patients are $214 billion in 2014 [2]. AD
imposes a sever burden on patients themselves as well as caregivers and public health
systems. Although it has been more than 100 years since Alois Alzheimer published
“About a Peculiar Disease of the Cerebral Cortex” in 1907 [3], the exact cause of AD is
yet to be identified. Amyloid β (Aβ) protein and hyperphosphorylated tau aggregates in
the brain are considered to be the key pathological hallmarks in AD patients [4, 5]. A
predominant mechanistic hypothesis for AD pathogenesis is the “amyloid cascade
hypothesis” that suggests that AD is caused by lack of Aβ clearance, which triggers
downstream neuronal injury such as synaptic and neuronal loss, enhanced
neuroinflammation, tau hyperphosphorylation, and eventually the clinical symptoms of
AD [6].

Aβ is a peptide of amino acids which is derived from amyloid precursor protein (APP)
cleaved by β- and γ-secretases [7, 8]. The γ-secretase cleavage occurs at position 40 or 42
of APP, yielding two major species of Aβ: Aβ40 (Aβ ending at residue 40) and Aβ42 (Aβ
ending at residue 42) peptides [7]. Although Aβ40 is the most abundant form of Aβ, Aβ42
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is less soluble and more neurotoxic than Aβ40 as it produces higher levels of Aβ
oligomers [9, 10].

In brains with AD, tau, a major neuronal microtubule-assembly-activator protein, is
abnormally hyperphosphorylated in neurofibrillary tangles (NFTs). The function of tau is
regulated by its degree of phosphorylation. Putatively, 85 phosphorylation sites have
been identified at serine, threonine, and tyrosine residues [11, 12] with approximately 45
specific sites identified for AD pathogenesis [13]. The abnormally hyperphosphorylated
tau reduces the binding affinity to microtubules, binds to normal tau to form insoluble
oligomers, and eventually develop NFTs which cause neurodegenerative diseases (called
tauopathy) [14].

HS-Aging
The clinical diagnosis of AD is a challenging process that requires to remove other
potential types of dementia. Many previous studies have compared the clinical diagnosis
of AD against the gold standard of autopsy confirmation and shown substantial AD
misdiagnosis [15-18]. The accurate diagnosis of AD is crucial to provide optimal
treatments for patients as well as to recruit participants in clinical trials for new therapies.
Hippocampal sclerosis of aging (HS-Aging) is one type of dementia that is often
clinically misdiagnosed as AD [19-21]. Clinical signs and symptoms of HS-Aging are
similar to those of AD with amnestic memory deficits [20, 21]. AD is characterized by
the accumulation of amyloid plaques and neurofibrillary tangles [22], while HS-Aging is
pathologically characterized by neuronal cell loss and gliosis in the hippocampus
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unilaterally (~50%) or bilaterally [20, 23]. HS-Aging is generally diagnosed postmortem.
The large majority of cases with HS-Aging show bilateral TAR DNA-binding protein 43
(TDP-43) pathology in limbic structures [24, 25]. TDP-43 pathology had been considered
to be a specific maker for frontotemporal lobar degeneration with ubiquitinated
inclusions (FTLD-U). However, TDP-43 pathology is found in both HS-Aging and AD;
in one study TDP-43 was detected in 71% of HS-Aging and 23% of AD cases [24]. There
is no known treatment or preventive care for HS-Aging so far. Understanding its genetic
architecture is important to reduce misdiagnosis with AD and to elucidate the aetiology
of HS-Aging, yielding new insights into the molecular-based mechanisms of the
underlying developmental process.

Brief history of genetic risks of AD and HS-Aging
Familial AD, which often occurs early in life, is linked mainly to mutations in three
genes: APP and the presenilin proteins (PSEN1 and PSEN2) [8], which generally cause a
shift in Aβ production from Aβ40 to less soluble and more neurotoxic Aβ42 (e.g., Volga
German mutation in PSEN2 and Iberian mutation in APP) [26-29], an increased total Aβ
levels (Swedish mutation in APP) [30], and an increased protofibril formation of Aβ
(Arctic mutation in APP) [31]. On the other hand, late-onset AD (LOAD), which often
occurs later in life and accounts for 95% of all AD cases [32], has more complex genetic
architecture. The ε4 allele of apolipoprotein E (APOE) gene is the major genetic risk
factor for LOAD. There are three apoE isoforms, apoE2 (cys112, cys158), apoE3
(cys112, arg158), and apoE4 (arg112, arg158), determined by rs429358 (T/C) and rs7412
(C/T) located on chromosome 19q13 (Table 1.1). The risk of AD is increased in
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individuals with the ε4 allele: 2 to 3 times in those with one ε4 allele, and more than 12time in those with two ε4 alleles, whereas the ε2 allele has a protective effect: 0.6 times
the odds compared to ε3/ ε3 carriers. These isoforms have different effects on Aβ
metabolism, influencing age of onset of Aβ deposition. It is suggested that the binding
ability of the apoE isoforms to Aβ follows the order of apoE2, apoE3, and apoE4, and
therefore apoE2 and apoE3 inhibit the aggregation and enhance the clearance of Aβ
compared to apoE4 [33]. The APOE alleles is also reported to be associated with tau
levels in CSF [34, 35]. This association, however, has not been established as thoroughly
as the association between APOE alleles and Aβ deposition [36].

The microtubule-associated protein tau (MAPT) gene on chromosome 17q21, encoding
tau and containing 16 exons, is also a candidate gene playing an important role in AD
development. The tau primary transcript contains 13 exons without exons 4A, 6 and 8 in
human brain. Exons 2, 3, and 10 are alternatively spliced, resulting in six different tau
isoforms with the range from 352 to 441 amino acids. These isoforms differ by the
presence of 0, 1, or 2 N-terminal inserts (0N = exons 2-3-; 1N = exons 2+3-; 2N = exons
2+3+) and either three (3R) of four (4R) microtubule binding repeats located at the C
terminus [37]. In the normal brain, the levels of 3R-tau and 4R-tau are approximately
equal. The mutations in MAPT alter the balance by increasing the ratio of 4R to 3R, and
disruption of the normal 4R to 3R ratio is associated with neurodegeneration by
accelerating phosphorylation of tau. However, the ratio is approximately 1 in the AD
brain with NFTs, and no mutations in MAPT have been found to be associated with AD
so far. Instead, the MAPT haplotypes associated with AD have been found. Two
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haplotypes exist in MAPT, directly oriented H1 and the inverted H2, which cover the
entire MAPT gene. These haplotypes are tagged by a 238bp H1 insertion/H2 deletion
polymorphism in intron 9 (del-In9). Many researchers reported that the H1 haplotype was
associated with risk of LOAD [38-40]. Since the H1 and H2 haplotypes do not alter
amino acid sequence, this pathogenic effect of the H1 haplotype may be due to
differences in the gene expression rather than tau protein structure [38].

In addition to the APOE alleles and MAPT haplotypes, a series of genome-wide
association studies (GWAS) have identified AD-associated single nucleotide
polymorphisms (SNPs) in or close to genes that include CR1, BIN1, INPP5D, MEF2C,
CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2, SLC24A4-RIN3, DSG2,
CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33, ZCWPW1, and CELF1
(Table 1.2) [41-45]. The report with the largest numbers of cases and controls was the
International Genomics of Alzheimer’s Project (IGAP), a consortium to discover the
genetic landscape of AD that included 74,046 individuals to show significant ADassociations with 19 SNPs by meta-analyzing GWAS from four component consortia
[41]. Although GWAS have succeeded in revealing numerous susceptibility SNPs for
AD, it is an ongoing challenge to identify functional loci and to understand how they
contribute to dementia pathogenesis.

Unlike AD, the APOE ε4 allele is not a genetic risk factor for HS-Aging [19, 21, 25, 46,
47]. The following four genes (in the chronological order they were so identified) have
been reported to harbor risk alleles associated with HS-Aging pathology: GRN on
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chromosome 17q, TMEM106B on chromosome 7p, ABCC9 on chromosome 12p, and
KCNMB2 on chromosome 3q [21, 48-53]. The T-alleles of GRN rs5848 and TMEM106B
rs1990622 were shown to have a risk of HS-Aging using an allele test, following the
known relationship of those two genes to frontotemporal lobar degeneration with TDP-43
inclusions (FTLD-TDP). The connections of the ABCC9 and KCNMB2 genes to HSAging risk were discovered via GWAS. The association of ABCC9 SNP rs704180 with
HS-Aging pathology was demonstrated using a recessive mode of inheritance (MOI)
[51]. Beecham and colleagues reported the KCNMB2 SNP rs9637454 as the top SNP for
HS pathology [48].

Genetic variants are located with much less frequency in coding regions than in noncoding regions (about only 1% are within a protein-coding sequence) [54]. However, it is
estimated that about 85% of the mutations with large effects on diseases are located in
protein-coding functional regions [55]. To understand disease development mechanisms
that underlie disease-associated genetic variants, identifying functional genes and/or
variants is an important challenge. Functional variants may be located in
nonsynonymous/synonymous coding regions, alternative splice region, and regulatory
regions such as promoter, operator, insulator, enhancer and silencer. A nonsynonymous
substitution includes a missense and nonsense mutations. The former alters the amino
acid sequence of a protein, and the later introduces a premature termination codon
resulting in a truncated protein. Many Mendelian diseases are due to nonsynonymous
mutations causing deleterious amino acid substitutions. Synonymous mutation occurs in
the coding region, but it does not change the amino acid sequence. These variants were
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referred to as “silent mutation” until recently [56]. However, several synonymous
mutations have been reported to affect mRNA splicing and stability, gene expression, and
protein folding and function [56]. Other disease-associated genetic variants are located in
the intronic and intergenic regions (i.e., non-coding regions) which may contain the
regulatory or splice sites. They may have an important role in regulating expression level
of disease-associated genes and modulating translation efficiency and stability [57].

As shown in Table 1.2, all 21 variants identified in IGAP are non-coding. To elucidate
the role of these SNPs, we hypothesized that each of the SNPs is: (1) a proxy of a coding
variant or (2) a regulatory variant. One frequently used approach for the first hypothesis
is to search coding variants in strong linkage disequilibrium (LD) with the variant
identified by GWAS. LD is generally measured using the squared correlation coefficient
(r2) between two variants, and the most widely used threshold is r2 ≥ 0.8. For the second
hypothesis, expression quantitative trait locus (eQTL) analysis can be used. eQTL is a
genetic locus that contributes to variation in gene expression. By mapping eQTL, we
could investigate how the SNPs regulate gene expression.

Rare variants and next-generation sequencing (NGS)
Rare variants have become a focus in the recent past. Although GWAS have been
successful in interrogating genetic variants for association with disease, GWAS are
performed under the “common disease – common variant” hypothesis positing that
common traits are caused by the combination of common variants with a small to
moderate effect [58]. GWAS rely on genotyping preselected SNPs and imputing
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ungenotyped variants based on local linkage disequilibrium (LD) of a set of some
haplotypes from reference population. Imputation approaches have continually improved
and are quite accurate for common variants [59, 60] but not as reliable for rare variants
[61]. Therefore, imputed rare variants are typically removed from GWAS analysis.

Recent advances in sequencing technologies have allowed to move toward
comprehensive genome-wide approaches, enabling to accurately genotype rare variants
generally defined as a variant with minor allele frequency (MAF) < 1-5%. These NGS
technologies have the potential to improve our understanding the role of both common
and rare variants in the underlying biological mechanisms of developing a disease.
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are ideal
approaches to identify novel variants and genes associated with complex traits. Most
coding variants, however, are very rare, and thus an extremely large sample size is
required to identify a single variant associated with a disease. There are significant
computational and statistical challenges for these sequencing studies. Traditional single
variant-based association tests, typically used for analysis of common variants, are
underpowered to detect rare variants unless sample size and/or effect size is very large
[62]. The disease-variant associations may be less accurate if computed by standard
regression method for evaluating the effect. Instead of testing single variant individually,
more powerful and computationally efficient approaches by aggregating the effects of
rare variants have become a standard approach for association testing.
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Many such approaches for testing association between rare variants within a pre-specified
region and a disease have been proposed. Sequence-kernel association test (SKAT) is one
of the most powerful rare variants analysis methods [63, 64]. The SKAT aggregates score
test statistics. It is powerful when both risk and protective variants are mixed and when a
small proportion of variants are causal [63]. Instead of summing up the square of
weighted score test statistics, burden test treats the square of the sum of weighed score
test statistics. The burden test is more powerful than SKAT when most of the variants are
causal and have the same direction of effect [63].

A recently-proposed scan-statistic-based test is another approach to detect the location of
rare variant clusters influencing disease. Scan-statistic-based test was introduced into
human genetics by Hoh et al [65] to locate susceptibility genes. Ionita-Laza et al. adapted
this test to identify clusters of rare risk variants based on a likelihood ratio under a
Bernoulli model proposed by Kulldorff [66] for disease association [67]. Variants within
a functional protein-coding domain may be located in close proximity and may play a
similar role in genetic mechanisms of a disease. Unlike association tests or other cluster
detection analyses, the scan-statistic-based test can both detect the location of clusters
and examine the association under the null hypothesis that probability of being a risk
variant within a certain scan window equals to that outside the window. This approach is
powerful when the disease risk variants significantly make a cluster in the window.
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Dissertation Outline
This dissertation work presents studies on gene-based association of genes with
hippocampal sclerosis of aging, translation of AD-associated polymorphisms into
functional candidates, and genetic regions containing rare variants associated with AD
identified by scan statistic-based approach.In Chapter two, gene-based association tests of
GRN, TMEM106B, ABCC9, and KCNMB2 and haplotype-based test of ABCC9 were
performed. The major findings from this study were that the significant gene-based
association between the ABCC9 gene and HS-Aging appeared to be driven by a region
with a significant haplotype-based association. In addition, the haplotype of ABCC9 was
associated with decreased ABCC9 expression. In Chapter three, the role of the noncoding SNPs identified in the IGAP consortium GWAS were elucidated within a systems
genetics framework. Systems genetics is a global approach to understand how genetic
information flows from DNA to transcripts, proteins, metabolites, and ultimately
diseases. Focusing on a causal relationship model in which SNP affects phenotype
through mRNA, each IGAP SNP was evaluated whether it is a proxy of a coding variant
or whether it is a regulatory variant. In Chapter four, genetic regions which contained risk
or protective rare variants associated with AD were identified using a scan-statistic-based
approach. The scan statistics with different settings were evaluated in TREM2 and
TOMM40 as highly-replicated positive controls. Very similar scan statistic values were
obtained when we specified the whole genome and chromosome as a large genetic
region. The optimized window approach captured almost the entire gene in TREM2 and
the single variant in TOMM40 as a meaningful cluster. Applying the optimized window
approach across the genome, clusters harboring risk or protective variants for AD were
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detected including within MUC6, NXNL1, and BCAM. The conclusion of the dissertation
and future research interests are discussed in Chapter Five.
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Table1.1. APOE isoforms encoded by two single nucleotide polymorphisms
rs429358
rs7412
Codon
Amino acid
Codon
Amino acid
apoE2
TGC
Cysteine
TGC
Cysteine
apoE3
TGC
Cysteine
CGC
Arginine
apoE4
CGC
Arginine
CGC
Arginine
A bold letter represents a nucleotide of each polymorphism
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Table1.2. Single nucleotide polymorphisms for Alzheimer’s Disease identified in the previous studies
1000 Genomes
Gene
Chr
SNP
Position
Annotation
References
MAF
r2
D’
CR1
1
207,692,049 Intron
0.17
[41, 43]
rs6656401
rs3818361
207,784,968 Intron
0.18
0.83 0.94 [42, 45]
rs6701713
207,786,289 Intron
0.18
0.83 0.94 [44, 45, 68]
rs1408077
207,804,141 Intron
0.18
0.83 0.93 [45, 69]
Regulatory region
BIN1
2
127,892,810
0.38
[41]
rs6733839
variant
rs744373
12,789,4615 Intergenic variant
0.27
0.49 0.90 [42, 45, 70]
rs7561528
127,889,637 Intergenic variant
0.31
0.35 0.69 [44, 45, 69]
INPP5D
2
234,068,476 Intron
0.46
[41]
rs35349669
MEF2C
5
88,223,420 Intron
0.37
[41]
rs190982
HLA-DRB56
32,578,530 Intergenic variant
0.26
[41]
rs9271192
DBR1
CD2AP
6
47,487,762 Intron
0.25
[41]
rs10948363
rs9296559
47,452,270 Intron
0.25
1
1 [42]
rs9349407
47,453,378 Intron
0.25
1
1 [42, 44, 68]
NME8
7
37,841,534 Intron
0.37
[41]
rs2718058
ZCWPW1
7
100,004,446 Intron
0.30
[41]
rs1476679
EPHA1
7
143,110,762 Intron
0.36
[41]
rs11771145
rs11767557
143,109,139 Intron
0.22
0.25 0.71 [42, 44]
PTK2B
8
27,195,121 Intron
0.34
[41]
rs28834970
A bold SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41].
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of
European ancestry; MAF = minor allele frequency

Table1.2. (Continued)
Gene
CLU

Chr
8

SNP

Position

Annotation

1000 Genomes
References
MAF
r2
D’
0.40
[41]
0.39
0.91 0.97 [43, 45]
0.30
0.28
1 [43, 71]
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27,467,686 Intron
27,464,519 Intron
27,468,862 5 prime UTR
Non coding
rs2279590
27,456,253
0.41
0.83 0.93 [43]
transcript exon
rs7982
27,462,481 Missense
0.39
0.90 0.97
Downstream gene
rs7012010
27,448,729
0.28
0.18 0.83
variant
Non coding
rs1532278
27,466,315 transcript exon
0.39
0.91 0.97 [44]
variant
CELF1
11
47,557,871 Intron
0.28
[41]
rs10838725
rs1057233
47,376,448 3 prime UTR variant
0.32
0.17 0.97 [72]
Downstream
MS4A
11
59,923,508
0.41
[41]
rs983392
intergenic
rs670139
59,971,795 Intron
0.40
0.44 0.97 [42, 44]
rs4938933
60,034,429 Intergenic
0.40
0.70 0.85 [44]
rs610932
59,939,307 3 prime UTR variant
0.44
0.72 0.89 [42, 45]
rs662196
59,942,757 Intron
0.44
0.69 0.88 [45]
rs583791
59,947,252 Missense
0.48
0.68 0.87 [45]
A bold SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41].
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of
European ancestry; MAF = minor allele frequency
rs9331896
rs11136000
rs9331888

Table1.2. (Continued)
Gene
PICALM

15

SORL1
FERMT2
SLC24A4RIN3
DSG2
ABCA7

Chr
11

SNP

Position

rs10792832

85,867,875

rs3851179

85,868,640

rs541458

85,788,351

rs561655

85,800,279

11
14

rs11218343
rs17125944

14

rs10498633

18
19

rs8093731
rs4147929
rs3764650
rs72973581

121,435,587
53,400,629

Annotation
Downstream
intergenic
Downstream gene
variant
Intergenic
Upstream gene
variant
Intron
Intron

92,926,952 Intron
29,088,958
1,063,443
1,046,520
1,043,103

1000 Genomes
MAF
r2
D’
0.37

References
[41]

0.37

0.99

0.99 [45, 73]

0.32

0.64

0.90 [43]

0.35

0.77

0.92 [44]

0.043
0.081

[41]
[41]

0.22

[41]

Intron
0.012
[41]
Intron
0.19
[41]
Intron
0.11
0.77 0.92 [42, 68]
Missense
0.053 0.012
1 [74]
Upstream gene
CD33
19
51,727,962
0.31
[41, 42, 44]
rs3865444
variant
Upstream gene
rs3826656
51,726,613
0.22
0.13
1
variant
rs12459419
51,728,477 Missense
0.31
1
1
CASS4
20
55,018,260 Intron
0.080
[41]
rs7274581
A bld SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41].
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of
European ancestry; MAF = minor allele frequency

CHAPTER TWO
Gene-based association study of genes linked to hippocampal sclerosis of aging
neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2

Abstract
Hippocampal sclerosis of aging (HS-Aging) is a common neurodegenerative condition
associated with dementia. To learn more about genetic risk of HS-Aging pathology, we
tested gene-based associations of the GRN, TMEM106B, ABCC9, and KCNMB2 genes,
which were reported to be associated with HS-Aging pathology in previous studies.
Genetic data were obtained from the Alzheimer’s Disease Genetics Consortium (ADGC),
linked to autopsy-derived neuropathological outcomes from the National Alzheimer’s
Coordinating Center (NACC). Of the 3,251 subjects included in the study, 271 (8.3%)
were identified as an HS-Aging case. The significant gene-based association between the
ABCC9 gene and HS-Aging appeared to be driven by a region in which a significant
haplotype-based association was found. We tested this haplotype as an expression
Quantitative Trait Locus (eQTL) using two different public-access brain gene expression
databases. The HS-Aging pathology protective ABCC9 haplotype was associated with
decreased ABCC9 expression, indicating a possible toxic gain of function.

Introduction
Hippocampal sclerosis of aging (HS-Aging) is a high-morbidity brain disease in people
of advanced age [75]. The prevalence of HS-Aging pathology ranges from 5 to 30% in
older people in large autopsy series [23, 47, 76, 77]. Clinical signs and symptoms of HS-
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Aging are similar to those of Alzheimer’s disease (AD) with amnestic memory deficits
[20, 21]. Because of the overlapping symptomology, HS-Aging is often clinically
misdiagnosed as AD [19-21]. AD is characterized by the accumulation of amyloid
plaques and neurofibrillary tangles [22], while HS-Aging is pathologically characterized
by neuronal cell loss and gliosis in the hippocampus seen by hematoxylin and eosin
(H&E) stain, which can occur unilaterally (~50%) or bilaterally [20, 23]. Whatever the
laterality on H&E stain, the large majority of cases with HS-Aging show bilateral TAR
DNA-binding protein 43 (TDP-43) pathology in limbic structures [24, 25]. Awareness of
this common cause of dementia is rapidly increasing, and we recently recommended a
revision of the terminology for describing this disease to cerebral age-related TDP-43
with sclerosis (CARTS) [78]. However, here we will maintain use of the term HS-Aging
because the neuropathologic databases we assessed did not include TDP-43 pathologic
information until quite recently.

Genetic risk factors for HS-Aging have been recently identified. Unlike AD, the
apolipoprotein E (APOE) ε4 allele is not a risk factor for HS-Aging [19, 21, 25, 46, 47].
By contrast, the following four genes (in the chronological order they were so identified)
have been reported to harbor risk alleles associated with HS-Aging pathology: Granulin
(GRN) on chromosome 17q, Transmembrane protein 106B (TMEM106B) on
chromosome 7p, ATP-binding cassette sub-family member 9 (ABCC9) on chromosome
12p, and potassium channel subfamily M regulatory beta subunit 2 (KCNMB2) on
chromosome 3q [21, 48-53].
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Alleles near the coding portions of the GRN and TMEM106B genes were shown to have
an association with HS-Aging using an allele test, following the known relationship of
those two genes to frontotemporal lobar degeneration with TDP-43 inclusions (FTLDTDP). Specifically, HS-Aging pathology was associated with the T-allele of the GRN
single nucleotide polymorphism (SNP) rs5848 [49, 53, 79, 80]. For the other FTLDrelated gene, TMEM106B, persons with eventual autopsy-proven HS-Aging pathology
were more likely to have the T-allele than controls [50, 53, 81]. We confirmed an
increase in HS-Aging odds for each copy of the T-allele of TMEM106B rs1990622 [51].

The connections of the ABCC9 and KCNMB2 genes to HS-Aging risk were discovered
via genome-wide association studies (GWAS), which are neither helped nor biased by
prior mechanistic hypotheses. The association of ABCC9 SNP rs704178 with HS-Aging
pathology was demonstrated in a GWAS using a recessive mode of inheritance (MOI)
[51]. The relationship of this locus with HS-Aging was subsequently tested in a different
group of research subjects, and the association was replicated [52]. Beecham and
colleagues reported the KCNMB2 SNP rs9637454 as the top SNP for HS pathology,
although this association was not genome wide significant [48], and has not been
replicated to date.

In the present study, we examined the associations of these four putative risk SNPs with
HS-aging pathology, using genetic data obtained from Alzheimer’s Disease Genetics
Consortium (ADGC) linked to neuropathological outcomes from the National
Alzheimer’s Coordinating Center (NACC) [51, 52]. Here we aggregated those data sets
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to attain greater statistical power for gene-wide association analyses, for the purpose of
understanding better the association of multiple (often co-inherited) gene variants with
disease development. Thus, we tested GRN, TMEM106B, ABCC9, and KCNMB2 for
gene-based associations with HS-Aging pathology by aggregating SNPs and indels (small
insertions or deletions) on each of those genes. In addition, we focused on the interesting
region located around intronic SNP rs704178 on the ABCC9 gene that was identified in
the previous work, and analyzed haplotype associations of the region with HS-Aging
pathology and ABCC9 gene expression.

Material and methods
Study subjects
ADGC genotype data were linked to data from the National Institute on Aging (NIA)funded 36 AD Centers (ADCs) and NACC registry phenotype information. Of 3,730
subjects with both genotype and autopsy information available to us, those who died at
age 60 years or older were included in this study. Cases of HS-Aging were identified as
patients who met at least one of the following criteria at autopsy; 1) the primary
pathologic diagnosis was hippocampal sclerosis, 2) there was a contributing pathologic
diagnosis of hippocampal sclerosis, or 3) medial temporal lobe sclerosis was present at
autopsy. We then excluded 180 individuals who had FTLD with ubiquitin-positive
inclusions, FTLD with no distinctive histopathology, FTLD-tau, or prion associated
disease (Figure 2.1).
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Quality control of the ADGC genotype data
Standard quality control (QC) procedures were performed on the ADGC genotype data
using PLINK v1.90a [82]. Markers were excluded based on the following criteria: (1)
minor allele frequency (MAF) < 1%; (2) call rate per variant (SNPs and indels) < 95%,
(3) Hardy-Weinberg equilibrium test in controls < 10−5. (Table 2.1). Samples were
excluded based on the following criteria: (1) call rate per individual < 95%, (2) a high
degree of relatedness per an estimated proportion of identical by descent (IBD) > 0.1875,
(3) excess of ± 3.0 standard deviations of heterozygosity rate. Of the 3,407 individuals
after the inclusion and exclusion criteria were applied, 3,330 passed the QC (Figure 2.1).

Identifying ethnic outliers
We performed principal component analysis (PCA) in EIGENSTRAT [83] using a
linkage disequilibrium (LD) pruned subset of markers (pairwise r2 < 0.2) from our data
merged to 1000 Genomes Project Phase 3 (1000 Genomes) [84] data after removing
symmetric SNPs and flipping SNPs discordant for DNA strands between the two
datasets. We then plotted the first and second principal components (PCs) for each
individuals (n = 5,834: 2,504 from 1000 Genomes and 3,330 from the study) using the
ggplot2 R package (version 2.2.0) [85] in R (version 3.2; http://www.r-project.org).
Based on the PC plot, 79 study subjects were removed as ethnic outliers (Figure 2.1 and
Figure 2.2). We reran the PCA for the remaining 3,251 European ancestries to derive
orthogonal PCs which were used as covariates in the subsequent analyses.
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Statistical analysis
Gene-based association analysis
Prior to gene-based association analyses, we performed the single variant association
testing using logistic regression assuming each of the three most commonly used MOI
(additive, dominant, and recessive) adjusted for age at death, sex and the top three PCs
using PLINK v1.90a [82]. Gene-based association analyses were conducted using
GATES (Gene-Based Association Test Using Extended Simes Procedure) [86] as
implemented in the open-source software Knowledge-Based Mining System for Genomewide Genetic Studies (KGG; version 3.5) [86]. GATES is a gene-based association test
that combines the p-values of variants within a gene obtained from single variant
association testing described above. We assigned variants to genes based on their
physical positions at the UCSC Genome Browser GRCh37/hg19 human assembly
(https://genome.ucsc.edu/) [87], and defined gene boundaries as ± 5kb from 5’ and 3’
untranslated regions (UTRs). This gene-based association test adjusts for LD in European
super population genotype data from the 1000 Genomes (1000 Genomes EUR) [84]. The
input data files to KGG contained four columns: chromosome number, marker ID,
marker position, and single variant association p-value. We then obtained overall pvalues for the associations of the target genes. Since those who live to advanced old age
have a higher risk of HS-Aging pathology [25, 88], there is a possibility that those who
died earlier would be always identified as a control even if they have a genetic risk.
Therefore, for sensitivity analysis against these possible misclassifications, we further
performed these gene-based association tests in cases and controls who died at age 80
years or older. For the gene-based association test, statistical significance level was
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deﬁned using the Bonferroni correction, yielding α = 0.05/(4 genes ×3 MOI ×2 age
groups) = 0.0021 for the four examined genes and three MOI.

Haplotype-based association analysis for HS-Aging
After identifying the HS-Aging risk-associated region on the ABCC9 gene by generating
a regional association plot using LocusZoom software [89], we performed additional post
hoc haplotype analysis for the variants on the region. First, we selected tag variants using
a pairwise SNP tagging approach with r2 ≥ 0.8 based on the 1000 Genomes EUR in
Haploview version 4.2 [90]. Maximum likelihood estimates of haplotype frequencies
were computed using an expectation-maximization (EM) algorithm implemented in the
functions haplo.em (for overall subjects) and haplo.group (for HS-Aging cases and
controls) of the haplo.stats R package (version 1.7.7) [91] using R (version 3.2;
http://www.r-project.org). The associations between common haplotypes (the estimated
frequencies greater than 1% in entire subjects) and HS-Aging status assuming a recessive
MOI were then tested with a haplotype score test adjusted for age at death, sex, and the
top three PCs [92] implemented in the function haplo.score. The global and haplotypespecific empirical p-values were obtained via 107 Monte-Carlo simulations.

Haplotype-based expression Quantitative Trait Locus (eQTL) analysis for ABCC9 gene
expression
We examined the association of the haplotypes with ABCC9 gene expression, focusing
on the haplotypes that were identified in association analysis for HS-Aging pathology.
We retrieved ABCC9 gene expression values in human brain and genotype data from two
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independent datasets: North American Brain Expression Consortium (NABEC) [93] and
United Kingdom Brain Expression Consortium (UKBEC) [94].

In the NABEC dataset, the expression data were available at Gene Expression Omnibus
(GEO) public repository (http://www.ncbi.nlm.nih.gov/geo/) under the GEO accession
GSE36192, consisting of two brain regions (cerebellum and frontal cortex) from 228
neurologically normal donors. The genotype data were obtained from the database of
Genotypes and Phenotypes (dbGaP: http://www.ncbi.nlm.nih.gov/gap) under the dbGaP
study accession phs000249.v2.p1. After the QC procedure with the same settings as we
did for the ADGC genotype data was applied, the genotype data were imputed using
Michigan Imputation Server (https://imputationserver.sph.umich.edu/start.html) [95] with
the following parameters: 1000 Genome Phase 3 v5 reference panel, Eagle v2.3 phasing
[96], and EUR population. The imputed genotype with posterior probabilities < 0.9 were
labeled as missing. Among the 228 NABEC subjects, 130 who died at age 30 years or
older and passed the QC were included in the analysis (all of them were US Caucasians).

In the UKBEC dataset, gene expression for ten brain regions (cerebellar cortex, frontal
cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, thalamus,
temporal cortex, and white matter) and genotype data from 134 “neuropathologically
normal” individuals were obtained at BRAINEAC website (http://www.braineac.org/).
The dosage files downloaded from the website (accessed 6/28/2016) were converted into
PLINK file format using Genome-wide Complex Trait Analysis (GCTA) software
version 1.24.4 [97]. The haplotype-based association analyses on ABCC9 gene
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expression were performed for the five haplotypes that were identified in the haplotypebased association analysis for HS-Aging assuming an additive MOI.

The analyses were carried out separately in the two datasets. We focused on ABCC9 gene
expression through Illumina probe ID ILMN_1751453 in frontal cortex of the NABEC
and through Affymetrix transcript ID t3446919 in the average of all ten regions of the
UKBEC dataset. Expression data were quantile normalized and log2-transformed.

Results
Of the 3,251 included subjects from ADGC/NACC, 271 (8.3%) met at least one of the
HS-Aging case criteria. Figure 2.3 shows the proportion of participants with HS-Aging
pathology increased with age at death, from 3.1% (95% confidence interval (CI) is 1.6 to
5.4%) in those aged less than 70 years to 15.7% (95% CI is 12.8 to 19.0%) in those aged
90 years or older. The mean age at death in the cases was significantly higher than that in
the controls (84.8 ± 8.4 years in the cases and 80.5 ± 8.8 years in the controls). No
statistically significant differences were noted by case status and sex, APOE ε4 and
microtubule-associated protein tau (MAPT) haplotype (H1 haplotype tagging rs8070723
A-allele and H2 tagging G-allele) frequencies (Table 2.2).

Single variant-based association
Table 2.3 shows the most associated variants on each of the four genes defined gene
boundaries as ± 5kb from 5’ and 3’ UTRs. The highest association signals came from
SNPs on the ABCC9 gene (rs7966849; p = 7.1 × 10-6 with an assumed recessive MOI and
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p = 4.4 × 10-5 with an assumed additive MOI) and on the KCNMB2 gene (rs73183328; p
= 8.2 × 10-5 with an assumed additive MOI and p = 1.6 × 10-4 with an assumed dominant
MOI). There was a series of small signals in high LD with the top SNP on the
TMEM106B gene, and there was an associated region with small effects in low-tomoderate LD with the top SNP on the ABCC9 gene.

Gene-based association
In the gene-based association analyses, 20, 222, 259 and 939 variants were mapped to the
GRN, TMEM106B, ABCC9 and KCNMB2 genes, respectively. Table 2.4 shows the
results of the gene-based association test in people aged 60 years. The ABCC9 gene had a
significant gene-based association with HS-Aging assuming a recessive MOI when
applying the Bonferroni correction (p = 2.4 × 10-4). There were nominally significant
gene-based associations for the GRN gene assuming a recessive MOI, the TMEM106B
gene assuming a recessive and an additive MOI, the ABCC9 gene assuming an additive
MOI, and the KCNMB2 gene assuming an additive and a dominant MOI. For sensitivity
analysis in people aged 80 years or older (n = 1,883: 203 in HS-Aging cases and 1,680 in
controls), we confirmed the same results that the ABCC9 gene had a significant genebased association with HS-Aging assuming a recessive MOI (p = 0.0017) (Table 2.5).

Haplotype-based association with HS-Aging
The single-variant-based association plots (Figure 2.4) imply that the significant genebased association of the ABCC9 gene is driven by the region in which the most
significant variants were located on the position 21,982,262 - 22,015,114 (all
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chromosomal positions we describe are referent to human assembly GRCh37/hg19). The
top SNP (rs7966849) in this study is in high LD with rs704180 (r2 = 0.926) which was
identified as the predominant risk SNP of HS-Aging [51, 52]. Assuming a recessive MOI,
there were 33 variants (30 SNPs and 3 indels) associated with HS-Aging pathology (each
with p < 1.0 × 10-3) in this region, all of which are intronic. We selected four tag SNPs
between exon 18 and 29 (Figure 2.4) of the ABCC9 gene when assuming a recessive
MOI. The most frequent haplotypes were “Hap1” T-A-G-T (from 5’ to 3’) estimated to
be present in 40.1% of observed chromosomes (32.1% in cases and 40.8% in controls),
and “Hap2” C-C-A-C (36.8%; 43.7% in cases and 36.2% in controls). Hap1 was
significantly associated with a lower risk of HS-Aging (score statistic = -2.747 and p =
0.0061) and Hap2 with a higher risk of HS-Aging (score statistic = 4.277 and p = 3.3 ×
10-5).

Haplotype-based expression Quantitative Trait Locus (eQTL) association with ABCC9
gene expression
In haplotype-based association tests assuming an additive MOI, Hap1 was significantly
associated with ABCC9 gene expression in both datasets (p = 0.0026 in the NABEC and
p = 0.024 in the UKBEC). Compared with the association with rs704180 only, Hap1 had
a stronger association with ABCC9 gene expression in the NABEC (Table 2.6).

Discussion
In the large autopsy dataset derived from multiple research centers, we evaluated the
genetic associations of four candidate genes (GRN, TMEM106B, ABCC9, and KCNMB2)
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for HS-Aging pathology. We found significant gene- and haplotype-based associations of
the ABCC9 gene with HS-Aging, and these approaches provide new insights into the
other candidate genes and variants that are associated with HS-Aging. The haplotype
made up of the risk alleles at the region (Hap2: C-C-A-C) was significantly
overrepresented in HS-Aging cases, and thus could be a risk haplotype, while the
opposite haplotype (Hap1: T-A-G-T) was significantly overrepresented in controls, and
thus could be a protective risk factor. We further revealed that the protective haplotype
(i.e., Hap1) was associated with down-regulation of ABCC9 gene expression, and the
results were consistent in two independent datasets.

Unlike the TMEM106B and GRN genes, the association between the ABCC9 gene and
FTLD-TDP has never been reported. That is, the ABCC9 gene could potentially be a key
gene on the distinction between FTLD-TDP and HS-Aging pathogenesis. The ABCC9
gene encodes a transmembrane protein, a part of an ATP-sensitive potassium (KATP)
channel complex. KATP channel consists of two distinct subunits: an inwardly rectifying
K+ channel (Kir6.x) and a regulatory sulfonylurea receptor (SURx) [98]. When the ATP
levels drop due to hypoxia/ischemia or other stressor, vascular smooth muscle cell KATP
channels open to increase K+ efflux, voltage-activated calcium channels close to block
Ca2+ entry, and in turn, vasodilatation is induced [99, 100]. Given the critical roles in
regulation of vascular tone, KATP channel dysfunction may be involved in cardio- and
cerebrovascular diseases. In mouse experiments, knock-out Kir6.1 (encoded immediately
downstream from ABCC9 on chromosome 12) and Abcc9 led to hypertension, coronary
artery vasospasm, and sudden cardiac death [101, 102]. In addition, Leverenz and
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colleagues found in their community-based study that HS-Aging cases were more likely
to have history of stroke, small vessel disease, and hypertension than AD cases [47]. Our
group also reported that brains with HS-Aging pathology tended to have
arteriolosclerosis in multiple cortical and subcortical regions [103]. We note that known
mutations in the human ABCC9 gene lead to a toxic gain of function (“Cantu syndrome”)
also are associated with human cerebrovascular pathology - a phenotype of “tortuous
cerebral vessels” detected on neuroimaging [104]. These prior studies imply that
cerebrovascular factors might be involved in developing HS-Aging via the KATP channeldependent activity [105]. In addition, we recently reported that human brain gene
expressions that are triiodothyronine (T3) responsive were correlated with the ABCC9
gene expression, and total T3 levels in cerebrospinal fluid (CSF) were significantly
higher in HS-Aging cases than in controls [106]. Prior studies showed links between
thyroid hormone (TH) levels and dementia [107-109], as well as TH levels and vascular
diseases [110-112]. Therefore it is possible that the ABCC9 gene variants may help
mediate links between TH dysregulation, cerebrovascular disease, and HS-Aging
pathology.

The TMEM106B gene did not have a significant gene-based association with HS-Aging
when applying the Bonferroni correction, but nominal significance was found assuming a
recessive and an additive MOI. Van Deerlin and colleagues identified rs1990622 T-allele
as a risk factor for FTLD with TDP inclusions (FTLD-TDP) [113]. Here we report that
rs3823612, which is in strong LD with rs1990622 (r2 = 0.975), is the variant on the
TMEM106B gene that is most strongly associated with risk for HS-Aging pathology
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assuming a recessive and an additive MOI. However, there are 108 gene variants (96
SNPs and 12 indels) in near perfect LD with the top SNP rs3823612 over the gene (the
range of r2 was from 0.930 to 0.996). Of the 108 variants, rs3173615 is a missense variant
on exon 6, rs6460901 is a splice region variant, rs2302634 and rs2302633 are non-coding
transcript exon variants, 19 variants are 5’ or 3’ UTR variants, 10 variants are upstream
or downstream gene variants, and the remaining variants are intronic. Yu and colleagues
reported that rs1990622 A-allele was associated with more advanced TDP-43 pathology
which is the dominant feature of HS-Aging [114]. TDP-43 is also a major disease protein
of other neurodegenerative diseases including FTLD and amyotrophic lateral sclerosis
(ALS) [115]. Nicholson and colleagues showed that rs3173615 (missense variant on exon
6), dictating the amino acid at codon 185 of threonine (ACC: T185) or serine (AGC:
S185), was associated with higher TMEM106B protein levels in GRN mutation carriers
[116]. Aberrant TDP-43 immunoreactivity is seen in both HS-Aging and FTLD-TDP,
and rs1990622 A-allele is reported to be a risk allele of both HS-Aging and FTLD-TDP.
However, these two diseases differ in clinical symptoms and pathological characteristics
[25, 117].

The SNP on the KCNMB2 gene that was identified as a possible risk factor is rs9637454
[48], while in the current study we found that rs73183328 was the most strongly
associated variant assuming an additive and a dominant MOI. Nominally significant
gene-based association of the KCNMB2 gene with HS-Aging were found assuming an
additive and a dominant MOI, although the gene-based associations were not significant
when applying the Bonferroni correction. The KCNMB2 protein is the transmembrane β2
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subunit of the large-conductance Ca2+- and voltage-activated K+ (BK) channel. The
channel is formed by pore-forming α-subunit encoded on the KCNMA1 gene
(chromosome 10) and four β-subunits (β1 to β4) [118]. The β2 subunit induces the BK
channel inactivation with the coexpressed α-subunit leading to neuronal excitability by
inhibiting K+ currents [119]. Since inactivating BK channels are found in CA1
hippocampal neurons [120], HS-Aging may be related to the KCNMB2 gene via a process
involving BK channel activation. It seems remarkable that both GWAS-identified
putative HS-Aging risk genes (ABCC9 and KCNMB2) encode proteins that modify
potassium channels.

There are limitations in this study. Since NACC data are derived from ADCs, the study
design is not population-based. Also, HS pathologic diagnoses vary across calendar time
and ADCs. Thus, there was probably some misclassification of HS-Aging diagnosis.
However, neuropathologic evaluation is the gold standard for HS diagnosis, and thus the
problem of misclassification, while ever-present, was minimized as much as possible. We
did not obtain dense genetic information on the GRN gene. The previously identified SNP
rs5848 as a HS-Aging risk SNP was removed in the process of the QC due to high
missing rate. Therefore, we could not evaluate the GRN gene well in this study.

In summary, we confirmed that the ABCC9 gene had the significant gene-based
association with HS-Aging when assuming a recessive MOI. The significant gene-based
association of the ABCC9 gene is driven by the region in which a significant haplotypebased association was found. Although we did not find statistically significant gene-based
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associations of the other three genes (i.e., GRN, TMEM106B, and KCMNB2) with HSAging in this study, it does not mean that these genes are not associated with HS-Aging.
Single variants may independently affect HS-Aging pathology rather than the entire gene,
or there may be interactions between these genes conferring HS-Aging risk via other
mechanisms, such as TDP-43 proteinopathies or ion channel dysfunction. In the future,
we plan to examine what role the intronic region of the ABCC9 gene plays in developing
HS-Aging pathology, and whether there are single variant-based and gene-based genegene interactions among these four genes to HS-Aging.
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Table 2.1. Quality control filters for single nucleotide polymorphism
Criteria
# of excluded variants # of passed variants
MAF < 1%
29,429,731
8,613,031
Call rate per variant < 95%
1,928,184
6,684,847
HWE test in controls < 10-5
19,386
6,665,461
MAF = minor allele frequency; HWE = Hardy-Weinberg equilibrium
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Table 2.2. Comparison of selected characteristics between hippocampal sclerosis of aging
cases and controls who died at age 60 years or older (n = 3,251)
Cases
Controls
Variable
p-value
n = 271
n = 2,980
Age at death, mean (SD)
84.8 (8.4)
80.5 (8.8)
<0.001
Sex, n (%)
Male
124 (45.8)
1,458 (48.9)
0.349
Female
147 (54.2)
1,522 (51.1)
APOE, n (%)a
-/114 (46.0)
1,207 (44.1)
0.749
-/ε4
109 (43.9)
1,216 (44.4)
ε4/ε4
25 (10.1)
314 (11.5)
b
MAPT (rs8070723), n (%)
H1/H1
176 (66.2)
1,773 (60.1)
0.146
H1/H2
77 (28.9)
1,022 (34.7)
H2/H2
13 (4.9)
154 (5.2)
a
APOE genotype information was available for n = 2,985.
b
MAPT genotype information was available for n = 3,215.
SD = standard deviation; APOE = apolipoprotein E; MAPT = microtubule-associated
protein tau.
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Table 2.3. Most associated variant with hippocampal sclerosis of aging in four genes using a logistic regression model assuming a
recessive/additive/dominant mode of inheritance in people who died at age 60 years or older (n = 3,251)
Risk/protective
RAF
RAF
Gene
MOI
Variant
OR (95% CI)a
p-value
alleles
in cases in controls
GRN
REC
rs72824731
C/G
9.5
8.4 3.88 (1.64 – 9.22)
0.0021
ADD
1.25 (1.02 – 1.53)
0.032
rs2879096
T/C
28.6
24.4
DOM
1.38 (1.07 – 1.78)
0.014
TMEM106B
REC
1.53 (1.19 – 1.98)
0.0011
rs3823612
G/C
64.6
56.5
ADD
1.40 (1.16 – 1.68)
3.6 × 10-4
DOM
rs13229988
A/G
64.0
56.4 1.67 (1.16 – 2.40)
0.0062
ABCC9
REC
1.84 (1.41 – 2.40)
7.1 × 10-6
rs7966849
A/G
60.3
51.2
ADD
1.46 (1.22 – 1.76)
4.4 × 10-5
DOM
rs829080
C/T
59.1
40.9 1.76 (1.18 – 2.62)
0.0057
KCNMB2
REC
rs13091964
T/C
96.1
92.9 1.84 (1.15 – 2.96)
0.011
ADD
2.42 (1.56 – 3.76)
8.2 × 10-5
rs73183328
A/G
5.0
2.2
DOM
2.40 (1.52 – 3.78)
1.6 × 10-4
a
Adjusted for age at death, sex and the top three principal components
MOI = mode of inheritance; RAF = risk allele frequency; OR = odds ratio; CI = confidence interval; REC = recessive; ADD =
additive; DOM = dominant

Table 2.4. Gene-based associations of the target four genes with hippocampal sclerosis of aging assuming a
recessive/additive/dominant mode of inheritance in people who died at age 60 years or older (n = 3,251)
Gene-based p-value
# of
Gene
Start position End position
variants
REC
ADD
DOM
GRN
20
42,417,491
42,435,470
0.012
0.16
0.090
TMEM106B
222
12,245,848
12,281,890
0.028
0.0089
0.068
ABCC9
259
21,945,324
22,094,628
2.4 × 10-4
0.0014
0.26
KCNMB2
939
178,249,224 178,567,217
0.57
0.0079
0.016
REC = recessive; ADD = additive; DOM = dominant
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Table 2.5. Gene-based associations of the target four genes with hippocampal sclerosis of
aging assuming a recessive/additive/dominant mode of inheritance in people who died at
age 80 years or older (n = 1,883)
Gene-based p-value
Gene
REC
ADD
DOM
GRN
0.24
0.035
0.026
TMEM106B
0.027
0.0032
0.0070
ABCC9
0.0017
0.0099
0.18
KCNMB2
0.23
0.014
0.015
REC = recessive; ADD = additive; DOM = dominant
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Table 2.6. Haplotype association with ABCC9 gene expression in human brain assuming
an additive mode of inheritance
NABEC
UKBEC
(Frontal cortex; n = 130 brains)
(10 brain regions; n = 134 brains)
Score statistic a
p-value
Score statistic a
p-value
Hap1
-2.968
0.0026
-2.250
0.024
Hap2
1.450
0.15
1.740
0.081
Hap3
1.686
0.091
-0.048
0.96
Hap4
0.214
0.83
-0.822
0.41
Hap5
0.878
0.38
1.952
0.051
Global
10.255
0.034
8.455
0.074
a

rs704180 only
0.010
A positive sign indicates up-regulation of ABCC9 gene expression and vice versa.

0.011

NABEC = North American Brain Expression Consortium (GEO accession: GSE36192);
UKBEC = United Kingdom Brain Expression Consortium (http://www.braineac.org/).
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Figure 2.1. Flow diagram of the subjects included in the analyses. Genetic data were
obtained from subjects in ADGC who had the NACC individual IDs. Phenotype data
were available from the neuropathological dataset in NACC. The inclusion/exclusion
criteria, quality control and removal of ethnic outliers were applied in order.
ADGC = Alzheimer’s Disease Genetics Consortium; NACC = National Alzheimer’s
Coordinating Center; NP = neuropathological dataset; HS-Aging = hippocampal sclerosis
of aging
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Figure 2.2. The first and second principal components plots along with 1000 genome
reference samples. Block dot indicates individuals in this study. We chose individuals
within the red dotted circle based on Euclidean distance from an individual with
maximum first and second principal components.
AFR = African; AMR = Admixed American; EAS = East Asian; EUR = European; SAS
= South Asian
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Figure 2.3. Proportion and 95% confidence interval of hippocampal sclerosis of aging
cases
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Figure 2.4. Estimation of haplotype frequencies and association using four tag single
nucleotide polymorphisms on the ABCC9 gene when assuming a recessive mode of
inheritance. Box indicates an exon.
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CHAPTER THREE
Translating Alzheimer’s disease risk polymorphisms into functional candidates
: a survey of IGAP genes

Abstract
Alzheimer’s disease (AD) is the most common form of dementia. The report with the
largest numbers of cases and controls was the International Genomics of Alzheimer’s
Project (IGAP), a consortium to discover the genetic landscape of AD that included
74,046 individuals to show significant AD-associations with 19 SNPs. However, we have
relatively little understanding of the functional impact of these loci in regards to AD
pathogenesis. In this study, we elucidated the role of the non-coding SNPs identified in
IGAP hypothesizing that each IGAP SNP is a proxy of a coding variant and/or a
regulatory variant. Our genetic data were obtained from the Alzheimer's Disease
Sequencing Project (ADSP). For the first hypothesis, rs2296160 in CR1, rs9270303,
rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982
in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 may be proxies of
coding SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in CELF1, and
rs8093731 in DSG2 may be regulatory SNPs affecting AD-associated gene expression.
Our approach for identifying proxies and examining eQTL lessens the impact of the
crude gene assignment, although this still remains an open question in the field.
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Introduction
Dementia is a clinical state caused by neurodegeneration and characterized by a loss of
function in cognitive domains and behavior. Alzheimer’s disease (AD) is the most
common form of dementia, accounting for over 50% of dementia cases [1]. Although it
has been more than 100 years since Alois Alzheimer published “About a Peculiar Disease
of the Cerebral Cortex” in 1907 [3], the exact cause of AD is yet to be identified.
Amyloid β (Aβ) protein and hyperphosphorylated tau aggregates in the brain are
considered to be the key pathological hallmarks in AD patients [4, 5]. A predominant
mechanistic hypothesis for AD pathogenesis is the “amyloid cascade hypothesis” that
suggests that AD is caused by lack of Aβ clearance, which triggers downstream neuronal
injury such as synaptic and neuronal loss, enhanced neuroinflammation, tau
hyperphosphorylation, and eventually the clinical symptoms of AD [6].

Familial AD, which often occurs early in life, is linked mainly to mutations in three
genes: amyloid precursor protein (APP) and the presenilin proteins (PSEN1 and PSEN2)
[8], which generally cause a shift in Aβ production from Aβ40 to less soluble and more
neurotoxic Aβ42 (e.g., Volga German mutation in PSEN2 and Iberian mutation in APP)
[26-29], an increased total Aβ levels (Swedish mutation in APP) [30], and an increased
protofibril formation of Aβ (Arctic mutation in APP) [31]. On the other hand, late-onset
AD (LOAD), which accounts for 95% of all AD cases [32], has a more complex genetic
architecture. The ε4 allele of apolipoprotein E (APOE) gene is the most well-established
susceptibility gene for LOAD. There are three apoE isoforms, apoE2 (cys112, cys158),
apoE3 (cys112, arg158), and apoE4 (arg112, arg158), determined by two single
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nucleotide polymorphisms (SNPs) rs429358 (T/C) and rs7412 (C/T) located on
chromosome 19q13. These isoforms have different effects on Aβ metabolism, influencing
age of onset of Aβ deposition. It is suggested that the binding ability of the apoE isoforms
to Aβ follows the increasing order of apoE2, apoE3 and apoE4, and thus apoE2 and
apoE3 inhibit the aggregation and enhance the clearance of Aβ compared to apoE4 [33].
The APOE alleles are also reported to be associated with tau levels in CSF [34, 35]. This
association, however, has not been established as thoroughly as the association between
APOE alleles and Aβ deposition [36].

A series of genome-wide association studies (GWAS) have identified AD-associated
SNPs in addition to the APOE alleles. The report with the largest numbers of cases and
controls was the International Genomics of Alzheimer’s Project (IGAP), a consortium to
discover the genetic landscape of AD that included 74,046 individuals to show significant
AD-associations with 19 SNPs by meta-analyzing GWAS from four component consortia
[41]. The SNPs are in or close to genes that include CR1, BIN1, INPP5D, MEF2C,
CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2, SLC24A4-RIN3, DSG2,
CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33, ZCWPW1, and CELF1
(Table 1.2). Although GWAS have succeeded in revealing numerous susceptibility
variants for AD, it is difficult to determine whether the genes and SNPs at these loci are
functional and to understand how they contribute to AD pathogenesis.

Genetic variants located in coding regions are much less frequent than those in noncoding regions (about only 1% of variants are within a protein-coding sequence) [54].
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However, it is estimated that about 85% of the mutations with large effects on diseases
are located in protein-coding functional regions [55]. To understand disease development
mechanisms that underlie AD-associated genetic variants, identifying functional genes
and/or variants is an important challenge. Functional variants may be located in a coding
region, an alternative splicing region, or a regulatory region such as promoter, operator,
insulator, enhancer or silencer. Nonsynonymous variants may have effects on the protein
structure and function. Many Mendelian diseases are due to nonsynonymous mutations
causing deleterious amino acid substitutions. Synonymous mutations occur in the coding
region but do not change the amino acid sequence. These variants were referred to as
“silent mutations” until recently [56]. Several synonymous mutations have been reported
to affect mRNA splicing and stability, gene expression, and protein folding and function
[56]. Other disease-associated genetic variants are located in the intronic and intergenic
regions (i.e., non-coding regions) which may contain regulatory or splice sites. Intronic
and intergenic variants may have an important role in regulating expression level of
disease-associated genes and modulating translation efficiency and stability [57].

In this study, we elucidated the role of the non-coding SNPs identified in the IGAP
consortium (hereinafter referred to as “IGAP SNPs”) within a systems genetics
framework. Systems genetics is a global approach to understand how genetic information
flows from DNA to transcripts, proteins, metabolites, and ultimately diseases [121].
Figure 3.1A shows three possible pathways linking a SNP, a transcript (mRNA), and a
phenotype [121-123]. The first model is the causal relationship model in which the SNP
affects phenotype by acting through mRNA. Second, the reactive model proposes that the
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SNP requires the phenotype to affect the mRNA. The third model is the independent
model in which the SNP affects mRNA and phenotype independently. Focusing on these
models in this study, we hypothesized that each IGAP SNP is: (1) a proxy of a coding
SNP (Figure 3.1B and 3.1C) or (2) a regulatory SNP (Figure 3.1D). One frequently used
approach to test the first hypothesis is to identify coding SNPs in strong linkage
disequilibrium (LD) with the SNP identified by GWAS. LD is generally measured using
the squared correlation coefficient (r2) between two SNPs, and the most widely used
threshold is r2 ≥ 0.8. For the second hypothesis, expression quantitative trait locus
(eQTL) analysis can be used. eQTL is a genetic locus that contributes to variation in gene
expression. By mapping eQTL, we investigate how the SNPs regulate gene expression.

Material and methods
Genetic datasets
Our genetic data were obtained from the Alzheimer's Disease Sequencing Project
(ADSP) with whole exome sequence (WES) data to limit the possibility of imputation
errors. ADSP is comprised of 18 cohorts from the Alzheimer's Disease Genetic
Consortium (ADGC) and 6 from the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium (Table 3.1). There were 10,913 unrelated subjects
with WES data in ADSP. For our study, we limited the subjects to those who had AD
diagnosis information and who were 65 years or older at the last visit or at death, yielding
a total of 10,468 ADSP subjects with WES data (Figure 3.2).

46

Gene expression datasets
Quality-controlled microarray gene expression from blood samples and whole genome
sequence (WGS) datasets were obtained from the Alzheimer's Disease Neuroimaging
Initiative (ADNI) database (available through http:// adni.loni.usc.edu). We included 661
subjects aged 65 years or older who had both gene expression and WGS data available.
We considered AD diagnosis (normal, mild cognitive impairment (MCI), or AD) closest
to the year when the blood sample was drawn.

We retrieved human brain gene expression and genotype dataset from the North
American Brain Expression Consortium (NABEC) [93] and United Kingdom Brain
Expression Consortium (UKBEC) [94]. Details are described in our previous report
[124]. Briefly, the NABEC gene expression data in two brain regions (cerebellum and
frontal cortex) were available at Gene Expression Omnibus (GEO) public repository and
the genotype data were obtained from the database of Genotypes and Phenotypes
(dbGaP: http://www.ncbi.nlm.nih.gov/gap). After performing standard QC procedures,
we imputed the genotype data using the Michigan Imputation Server
(https://imputationserver.sph.umich.edu/start.html) [95, 96] with the following
parameters: 1000 Genome Phase 3 v5 reference panel, Eagle v2.3 phasing [96], and EUR
population. Of the 228 neurologically normal donors, 119 subjects who died at age 65
years or older and passed QC were included in the analysis (all were US Caucasians).
The UKBEC gene expression in ten brain regions (cerebellar cortex (CRBL), frontal
cortex (FCTX), hippocampus (HIPP), medulla (MEDU), occipital cortex (OCTX),
putamen (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal cortex (TCTX),
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and white matter (WHMT)) and the genotype data in 134 neuropathologically normal
individuals were obtained from the BRAINEAC website (http://www.braineac.org/). The
dosage genotype data were converted into PLINK file format using Genome-wide
Complex Trait Analysis (GCTA) software version 1.24.4 [97].

Since the NABEC and UKBEC datasets do not have AD diagnosis information, we
obtained two datasets to examine whether the levels of gene expressions were different
between AD statuses. The first dataset was derived from AD cases and controls available
at Gene Expression Omnibus (GEO) public repository
(http://www.ncbi.nlm.nih.gov/geo/) under the GEO accession GSE5281 [125]. The gene
expression data consisted of 9 AD cases and 13 controls in entorhinal cortex (EC), 10 AD
cases and 12 controls in hippocampus (HIPP), 16 AD cases and 12 controls in medial
temporal gyrus (MTG), 8 AD cases and 13 controls in posterior cingulate (PC), 23 AD
cases and 11 controls in superior frontal gyrus (SFG), and 19 AD cases and 12 controls in
primary visual cortex (VCX). The range of age at death was 63 to 102. The second was
Allen Institute data downloaded at http://aging.brain-map.org/ derived from 38 AD cases
and 47 controls (AD diagnosis was based on NINCDS-ADRDA Alzheimer's Criteria) in
white matter (FWM), hippocampus (HIPP), parietal cortex (PCx), and temporal cortex
(TCx) brain regions. The range of age at death was 77 to 100+.

We excluded probes in Affymetrix that targeted transcripts from different genes (i.e.,
probes with “_x” suffix) if a more reliable probe was available. We also excluded
monoallelically expressed genes including genes on chromosomes X and Y, and HLA-
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genes (i.e., HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB,
HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA,
HLA-DRB1, HLA-DRB5, HLA-E, HLA-F, HLA-G, HLA-J, HLA-P, and HLA-T).
Expression data were normalized and log2-transformed.

Statistical analysis
Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs
For each of the 21 IGAP SNPs (including CD33 and DSG2, although the SNPs
rs3865444 and rs8093731 were reported not to reach statistical significance on metaanalysis in IGAP [41]), we first identified SNPs in the nearby coding-regions showing
strong LD (r2 ≥ 0.8) and moderate LD (0.4 ≤ r2 < 0.8) by using 1000 Genomes Project
Phase 3 in individuals of European ancestry (1000 Genomes EUR) [84]. We performed
association tests under an additive mode of inheritance (MOI) assumption for the coding
SNPs, using logistic regression adjusted for age at the last visit or death, sex, and the top
5 principal components (computed in PLINK v1.90a [82]). The pathogenic nature of
nonsynonymous SNPs associated with AD was predicted by SIFT (http://sift.jcvi.org/)
[126] and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) [127] which are in silico
algorithm tools to predict the effect of amino acid substitution on a protein function.

Hypothesis 2: identified IGAP SNPs are regulatory SNPs
We evaluated whether the IGAP SNPs were cis- or trans-eQTL on the same chromosome
as genes. We defined a locus within 1Mb of the 5′ or 3′ ends of the gene as cis-eQTL, and
a locus more than 1Mb away from the transcription site as a trans-eQTL (Figure 3.1E).
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We first tested the association between each of the IGAP SNPs and each of all the gene
expression profiles, assuming an additive MOI as implemented in PLINK v1.90a [82].
We then examined whether the levels of gene expression modified by the IGAP SNPs
were different between AD statuses. An analysis of covariance (ANCOVA) with sex and
age as covariates was applied to each comparison for all gene expressions identified in
the eQTL analysis.

For all analyses, we converted the nominal p-values into false discovery rate adjusted pvalues (FDR adjusted p-value) using the Benjamini-Hochberg procedure [128] and
defined associations with FDR adjusted p-value < 0.05 as significant.

Results
We considered individuals with either prevalent or incident AD at baseline (year 0) as
AD cases in ADSP. Descriptive characteristics of the individuals are shown in Table 3.2.
5,374 (51.3%) were AD cases.

Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs
We identified 10 exonic SNPs which were in strong LD (r2 ≥ 0.8) and 16 SNPs in
moderate LD (0.4 ≤ r2 < 0.8) with the IGAP SNPs based on 1000 Genomes EUR (Table
3.3). We confirmed that the several exonic SNPs demonstrated statistically significant
associations with AD after FDR adjustment, including rs2296160 in CR1, rs9270303,
rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982
in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 (Table 3.4). The
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association between rs4844600 in CR1 and AD was not confirmed because of the lack of
WES data in ADSP. Of these 10 coding SNPs, 5 SNPs (rs2296160 in CR1, rs9270303 in
HLA-DRB1, rs1859788 in PILRA, rs3752246 in ABCA7, and rs7232 in MS4A6A) are
nonsynonymous (Table 3.5). When we analyzed the nonsynonymous SNPs with SIFT
and Polyphen-2, rs2296160, rs9270303, rs1859788, and rs3752246 were predicted to
have minimal impact on their respective proteins (Table 3.5). In contrast, the minor allele
of rs7232 was predicted to be deleterious and possibly damaging to MS4A6A protein.

Hypothesis 2: identified IGAP SNPs are regulatory SNPs
Table 3.6 shows gene expressions in the blood that were significantly associated with the
IGAP SNPs, reaching FDR adjusted significance level. We found that the protective
allele of rs1476679 in ZCWPW1 was strongly associated with decreased expression of
multiple PILRB probe sets and TRIM4 expression, and associated with increased
expressions of ZKSCAN1I, GATS, and PVRIG. The protective allele of rs11771145 in
EPHA1 was associated with increased LOC154761 expression. The risk allele of
rs28834970 in PTK2B exhibited cis-eQTL for multiple probe sets for its own expression
and for the contiguous gene TRIM35. This allele also had trans-association with NSAP11.
The risk allele of rs10838725 was associated with increased MYBPC3 expression. The
protective allele of rs983392 was associated with decreased expressions of MS4A6A and
another family members, MS4A4A. The protective alleles of rs8093731 in DSG2 and
rs7274581 in CASS4 appeared to be trans-eQTLs. Of these significant gene expressions
in the blood, only MYBPC3 (11725151_at) potentially regulated by the CELF1 SNP was
significantly associated with AD status.
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The FDR adjusted significant associations between the IGAP SNPs and brain gene
expressions in NABEC and UKBEC are shown in Table 3.7. In NABEC, the protective
allele of rs10792832 in PICALM was significantly associated with increased expression
of MRGPRD in CRBL. The protective allele of rs8093731 in DSG2 exhibited transeQTL for the expression of three genes, DLGAP1, NETO1, and KCNG2. The minor allele
of rs7274581, which is also protective, was significantly associated with the PCK1
expression in CRBL. Of these patterns, the DLGAP1 and NETO1 expressions in FCTX
were highly correlated (r2 = 0.78) (Figure 3.3). In UKBEC, rs6656401 in CR1 acted as an
eQTL for several genes, COL9A2, CERS2 (also known as KASS2), ARHGEF2, CNTN2,
and CDK18 (also known as PCTK3 and PCTAIRE3) in MEDU, and CR1 itself in the
average of all ten regions (AveALL) and WHMT. The genes potentially regulated by the
CR1 SNPs were highly correlated with each other except CR1 expression (r2 = 0.68 to
0.89) (Figure 3.4).

In comparison with AD controls using GSE5281, AD cases had significantly lower
expressions of DLGAP1 in MTG and SFG, NETO1 in EC, MTG, PC, and SFG, KCNG2
in MTG, CR1 in MTG, and ARHGEF2 in EC. On the other hand, AD cases had
significantly higher expressions of DLGAP1 in HIP, COL9A2, CERS2, and CR1 in EC,
and ARHGEF2 in PC (Table 3.8 and Table 3.9). For the Allen Institute dataset,
significantly higher expressions of KCNG2, CNTN2, ARHGEF2, and CDK18 in AD
cases have seen only in TCx (Table 3.10).
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Discussion
Although recent studies have identified novel GWAS loci that affect AD risk, we have
relatively little understanding of the functional impact of these loci in regards to AD
pathogenesis. In this study, we examined the possible functional effects of the IGAP
SNPs on AD under two hypotheses: “the IGAP SNP is a proxy of a coding SNP” and
“the IGAP SNP is a regulatory SNP”. For the first hypothesis, rs2296160 in CR1,
rs9270303, rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in
ZCWPW1, rs7982 in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 are
proxies of coding SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in
CELF1, and rs8093731 in DSG2 are associated with gene expression, although whether
these SNPs are proxies for the functional regulatory SNP or functional themselves
requires further studies.

Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs
CR1 SNPs
The IGAP SNP rs6656401 in CR1 was the most striking SNP in this study for several
reasons. First, there were 2 coding SNPs (one is synonymous and the other is
nonsynonymous) in strong LD with the IGAP SNP. Second, the IGAP SNP acted as cisor trans-eQTL for the several gene expressions in the brain. Last, these expressions were
associated with AD. CR1, located on chromosome 1q32.2, encodes complement receptor
1 in a cluster of complement-related proteins which plays an important role in the
immune system [129]. The CR1 protein is a receptor for complement fragments binding
to Aβ, and thus the change in CR1 protein structure and expression levels may be related
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to Aβ clearance [130]. We found the two coding SNPs, rs4844600 and rs2296160, which
were in strong LD with the IGAP SNP rs6656401. The coding SNP rs2296160 is
nonsynonymous, causing alanine-to-threonine amino acid substitution at codon position
2419 (A2419T), while the SNP rs4844600 is synonymous (E60E). The IGAP SNP as
well as the coding SNPs acted as cis-eQTL for CR1 expression itself (Figure 3.5). The
most associated SNP with the CR1 expression was the nonsynonymous SNP rs2296160.
This may imply that the change in CR1 protein structure may change the expression level
of the gene itself through an autoregulatory mechanism.

Furthermore, the higher CR1 expression detected by the probe set 244313_at in EC
increased the risk of AD in GSE5281 dataset. Consistent with our findings, the SNP
rs1408077 in CR1, which is in strong LD with the IGAP SNP rs6656401, was reported to
be associated with loss of EC thickness [69], and the IGAP SNP rs6656401 A carriers
had smaller local gray matter volume in EC of young health adults which may lead to an
increased risk of LOAD [131]. These results may indicate that there is a causal
relationship between CR1 SNPs, CR1 expression, and AD development, although we
cannot mention which model this relationship is on: causal model or reactive model in
Figure 3.1.

Other gene expressions than CR1 potentially regulated by CR1 SNPs were highly
correlated with each other in MEDU in UKBEC. These genes are highly expressed in
oligodendrocytes
(http://web.stanford.edu/group/barres_lab/brainseqMariko/brainseq2.html) [132]. The
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COL9A2 and CERS2 genes were over-expressed in EC of AD cases. The ARHGEF2 gene
was over-expressed in PC and TCx of AD cases and under-expressed in EC of AD cases.
The genes CNTN2 and CDK18 were significantly over-expressed in TCx of AD cases. In
future work, gene co-expression network analysis will be required to understand how
these gene expressions affect in each of the brain regions of AD cases.

ZCWPW1 SNPs
ZCWPW1 (zinc finger, CW type with PWWP domain 1) is located on chromosome
7q22.1. We found two coding SNPs, rs2405442 and rs1859788, which were in strong LD
with the IGAP SNP rs1476679. The coding SNP rs1859788 is nonsynonymous, causing
glycine-to-arginine amino acid substitution at codon positions 78 (G213R). The IGAP
SNP as well as the coding SNPs acted as cis-eQTLs for three gene expressions (GATS,
TRIM4, and PILRB) in the blood, although we did not find significant associations
between these blood gene expressions and AD.

MS4A6A SNPs
MS4A6A, located on chromosome 11q12.2, encodes a member of membrane-spanning
4A gene family (membrane-spanning 4A domains, subfamily A, member 6A). We also
found two coding SNPs, rs12453 and rs7232, which were in strong and moderate LD
with the protective IGAP SNP rs983392. The coding SNP rs7232 is nonsynonymous,
causing threonine-to-serine amino acid substitution at codon positions 213 (T213S),
while the SNP rs12453 is synonymous (L137L). The IGAP SNP as well as the coding
SNPs affected MS4A6A expression itself and its gene family MS4A4A in the blood.
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However, we did not find FDR adjusted significant associations between these blood
gene expressions and AD. MS4A genes are highly expressed in hematopoietic cells, and
involved in the regulation of calcium signaling [133]. Although the function of MS4A6A
protein are still unknown, it is possible that the MS4A6A SNPs is linked to AD via
deregulation of calcium signaling implicated in neurodegenerative diseases [134, 135].

CLU SNPs
We confirmed synonymous SNP rs7982 was in strong LD with the IGAP SNP rs9331896
and was protectively associated with AD. However, we found no significant gene
expressions regulated by the CLU IGAP SNP and the synonymous SNP. CLU, also
known as apolipoprotein J, is located in chromosome 8p21.1, and encodes clusterin.
Clusterin directly influences Aβ, regulating the conversion of Aβ into insoluble forms
[136, 137]. CLU has mainly two isoforms, nuclear CLU (nCLU, isoform 1) and secretary
CLU (sCLU, isoform 2) with different functions. The sCLU form is pro-survival, while
nCLU is pro-apoptotic [138]. Since the coding SNP rs7982 is synonymous, it would
affect alternative splicing as Ling et al. showed that the protective SNP rs11136000
(which is in almost perfect LD with rs7982 in 1000 genomes EUR) was associated with
increased nCLU expression level [139]. We would need to examine how the isoforms
affects Aβ clearance in future.

HLA-DRB5-DRB1 SNPs
The IGAP SNP rs9271192 is located in intergenic region (chromosome 6p21.32),
contiguous to HLA class II genes (HLA-DR, -DQ and -DP). There were two coding
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SNPs which were in strong or moderate LD with the IGAP SNP: the nonsynonymous
rs9270303 is in HLA-DRB1 and the synonymous rs1049092 is in HLA-DQB1. Several
HLA-DR and HLA-DQ genes are monoallelically expressed. There are three classes of
monoallelically expressed genes [140, 141]. One is the autosomal imprinted genes
regulated in a parent-of-origin specific manner. The second one is X-inactivated. The last
class is for randomly monoallelically expressed genes in autosome, in which several
immune system genes are included [140, 141]. Given epigenetic association between
DNA methylation in HLA-DRB5 and AD pathology [142], allele specific expression may
impact on biological function related to AD.

ABCA7 SNPs
We confirmed that nonsynonymous SNP rs3752246 was in strong LD with the IGAP
SNP rs4147929 and was associated with AD risk. However, we found no significant gene
expressions regulated by the ABCA7 IGAP SNP or the nonsynonymous SNP. ABCA7 is
located in chromosome 19p13.3, and encodes a member of the superfamily of ATPbinding cassette transporters. ABCA7 is expressed in microglia and oligodendrocytes
[143] and potentially regulates lipid efflux and Aβ accumulation [144, 145]. Several
SNPs in or close to ABCA7 were identified as AD risk alleles [41, 42, 68]. However, the
impact of these SNPs is not yet well understood.

Hypothesis 2: identified IGAP SNPs are regulatory SNPs
In CELF1, we did not have sufficient evidence that the IGAP SNP rs10838725 and the
coding SNP rs2293576 in strong LD with the IGAP SNP were associated with AD.
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However, rs10838725 acted as cis-eQTL for MYBPC3 expression in the blood which was
associated with AD. MYBPC3 is located on chromosome 11p11.2, and encodes cardiac
myosin binding protein C expressed exclusively in heart muscle [146]. Huang et al.
reported that the MYBPC3 and SPI1 were associated with the allele of rs1057233 in
CELF1 (r2 = 0.17 and D’ = 0.97 with the IGAP SNP rs10838725 as shown in Table 1.2),
and suggested that the association of MYBPC3 expression came from leaky transcription
driven by the adjacent SPI1 expression [72].

In addition to CR1, several IGAP SNPs were associated with gene expression in the
brain. DLGAP1 and NETO1 expressions were regulated by the DSG2 IGAP SNP and
were highly correlated with each other in FCTX. Interestingly, these genes were
significantly under-expressed in MTG and SFG brain region of AD cases. The DSG2
IGAP SNP also regulated KCNG2 expression which was under-expressed in MTG of AD
cases as well, although it was not correlated with the DLGAP1 and NETO1 expressions.
DLGAP1 is located in chromosome 18p11.31 more than 25Mb away from DSG2, and
encodes disks large-associated protein 1 (also known as guanylate kinase- associated
protein (GKAP)). NETO1 is located in chromosome 18q22.3 more than 40Mb away from
DSG2 and encodes neuropilin and tolloid like 1. Both DLGAP1 and NETO1 are mainly
expressed in neuros
(http://web.stanford.edu/group/barres_lab/brainseqMariko/brainseq2.html) [132], and
may be involved in the N-methyl-D-aspartate receptor-dependent synaptic plasticity [147,
148]. KCNG2 located in chromosome 18q22.3, encodes a voltage-gated potassium
channel subfamily G member 2, which is a potassium channel subunit. Potassium
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channels are important regulatory proteins also associated with synaptic plasticity [149].
Synaptic plasticity is a fundamental property of the nervous system [150, 151]. Elevated
Aβ levels induce synaptic dysfunction, and thus loss of synaptic proteins may contribute
to AD progression. Although the role of DSG2 gene is unknown, this may imply that
DSG2 is involved in brain functions including memory and learning.

There are limitations to this study. We aggregated data from many rich resources that aid
in establishing a confluence of related information; however, these datasets are
heterogeneous and can exhibit biases from the respective study designs, analytic
protocols, and participant pools. As per common but inexact convention, we identified
genes as those closest to the identified IGAP SNP. Although our approach for identifying
proxies and examining eQTL lessens the impact of this crude gene assignment, this still
remains an open question in the field.

In summary, investigating the functional role of the suspected and replicated SNPs
associated with AD is an important next step to understanding the genetic contributions
and the functional pathways linking AD developmental mechanisms. AD is a complex
disease with a strong genetic component. However, much of the genetic contribution to
AD remains unexplained. In future studies, we will need to investigate how RNA and
protein levels as well as their interactions are affected the known genes.
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Table 3.1. ADGC and CHARGE studies in ADSP
Consortium
Study
ADGC
ACT
ADC
CHAP
EFIGA
GDF
MAP
MAYO
MAYO PD
MIA
MIRAGE
NCRAD
NIA-LOAD
RAS
ROS
TARCC
TOR
VAN
WHICAP
CHARGE
ARIC
ASPS
CHS
ERF
FHS
RS
ADGC = Alzheimer's Disease Genetic Consortium; CHARGE = Cohorts for Heart and
Aging Research in Genomic Epidemiology; ADSP = Alzheimer's Disease Sequencing
Project; ACT =Adult Changes in Thought; ADC = NIA Alzheimer Disease Centers;
CHAP = Chicago Health and Aging Project; EFIGA = Estudio Familiar de la Influencia
Genetica en Alzheimer; GDF = Genetic Differences; NIA-LOAD = National Institute on
Aging (NIA) Late Onset Alzheimer's Disease Family Study; MAP = Memory and Aging
Project; MAYO = Mayo Clinic; MAYO PD = Mayo PD; MIA = University of Miami;
MIRAGE = Multi-Institutional Research in Alzheimer's Genetic Epidemiology; NCRAD
= National Cell Repository for Alzheimer's Disease; RAS = University of Washington
Families; ROS = Religious Orders Study; TARCC = Texas Alzheimer's Research and
Care Consortium; TOR = University of Toronto; VAN = Vanderbilt University;
WHICAP = Washington Heights-Inwood Columbia Aging Project; ARIC =
Atherosclerosis Risk in Communities Study; ASPS = Austrian Stroke Prevention Study;
CHS = Cardiovascular Health Study; ERF = Erasmus Rucphen Family; FHS =
Framingham Heart Study; RS = Rotterdam Study
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Table 3.2. Characteristics of the individual in ADSP
Overall
AD cases
AD controls
Variable
n (%)
n (%)
n (%)
ADSP (n = 10,468)
5,374 (51.3)
5,094 (48.7)
Sex
Male
4,380 (41.8)
2,313 (43.0)
2,067 (40.6)
Female
6,088 (58.2)
3,061 (57.0)
3,027 (59.4)
Age at the last visit or at death
65-69
570 (5.5)
537 (10.0)
33 (0.6)
70-74
1,127 (10.8)
1,062 (19.8)
65 (1.3)
75-79
1,355 (12.9)
1,153 (21.5)
202 (4.0)
80-84
2,650 (25.3)
1,092 (20.3)
1,558 (30.6)
84-90
3,139 (30.0)
896 (16.7)
2,243 (44.0)
90+
1,627 (15.5)
634 (11.8)
993 (19.5)
APOE
-/7,476 (71.4)
3,140 (58.4)
4,336 (85.1)
-/ε4
2,900 (27.7)
2,159 (40.2)
741 (14.5)
ε4/ε4
91 (0.9)
75 (1.4)
17 (0.3)
ADSP = Alzheimer's Disease Sequencing Project; APOE = apolipoprotein E
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Table 3.3. Exonic single nucleotide polymorphism correlated with the IGAP SNP
Exonic SNP
Closest
IGAP SNP
Gene
SNP ID
Position
Variant a Alleles b
Strong LD (r2 ≥ 0.8)
rs6656401

CR1

1000 Genomes EUR
Gene

MAF

r2

D’
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rs4844600
207,679,307
E60E
G/A
CR1
0.19 0.88
0.99
rs2296160
207,795,320 A2419T
G/A
CR1
0.18 0.84
0.93
rs9271192
HLA-DRB5 rs9270303
32,557,483
A13T
C/T
HLA-DRB1
0.25 0.92
0.99
rs1476679
ZCWPW1
rs2405442
99,971,313
L12L
C/T
PILRA
0.32 0.85
0.97
rs1859788
99,971,834
G78R
G/A
PILRA
0.32 0.85
0.97
rs9331896
CLU
rs7982
27,462,481
H263H
G/A
CLU
0.39 0.90
0.97
rs10838725 CELF1
rs2293576
47,434,986
A191A
G/A
SLC39A13
0.31 0.84
0.99
rs983392
MS4A6A
rs12453
59,945,745
L137L
T/C
MS4A6A
0.40 0.80
0.91
rs4147929
ABCA7
rs3752246
1,056,492 A1527G
C/G
ABCA7
0.19 0.97
1
rs3865444
CD33
rs12459419
51,728,477
A14V
C/T
CD33
0.31
1
1
a
b
The first amino acid is linked to major allele and the second one to minor allele. Major/minor alleles
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; MAF = minor allele frequency; LD=
linkage disequilibrium; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of European ancestry

Table 3.3. (Continued)
Closest
IGAP SNP
Gene
2
Moderate LD (0.4 ≤ r < 0.8)
rs9271192

HLA-DRB5

SNP ID
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rs2308759
rs1049092
rs1049086
rs2722372
rs2598044
rs909152
rs12286721
rs7232
rs16961975
rs61730311
rs4147930

Exonic SNP
Position
Variant a

1000 Genomes EUR
Alleles

b

Gene

MAF

r2

D’

V130V
C/T
HLA-DRB1
0.14 0.45
1
D201D
G/A
HLA-DQB1
0.40 0.51
0.97
D167D
G/A
HLA-DQB1
0.40 0.50
0.97
rs2718058
NME8
R43K
G/A
NME8
0.25 0.49
0.93
D59D
C/T
NME8
0.25 0.49
0.93
rs1476679
ZCWPW1
G337G
C/T
LRCH4
0.31 0.53
0.75
rs10838725 CELF1
I671M
A/C
AGBL2
0.28 0.48
0.97
rs983392
MS4A6A
T213S
T/A
MS4A6A
0.36 0.68
0.92
rs8093731
DSG2
G/A
DSG3
0.012 0.51
0.75
29,046,606 V509M
C/T
DSG3
0.010 0.67
0.90
29,049,138 R575W
rs4147929
ABCA7
A/G
ABCA7
0.28 0.56
1
1,064,193 L1995L
T/G
ABCA7
0.28 0.55
0.98
rs4147934
1,065,018 S2045A
D275E
T/A
HMHA1
0.27 0.56
0.97
rs2074442
1,074,000
P603P
C/G
HMHA1
0.26 0.49
0.88
rs2074454
1,080,311
rs10404947
Q769Q
G/A
HMHA1
0.22 0.44
0.74
1,081,617
rs3865444
CD33
rs35112940
51,738,917
G304R
G/A
CD33
0.21 0.57
0.98
a
The first amino acid is linked to major allele and the second one to minor allele.
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; MAF = minor allele frequency; LD=
linkage disequilibrium; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of European ancestry
32,549,596
32,629,802
32,629,904
37,890,267
37,890,316
100,175,473
47,701,528
59,940,599

Table 3.4. Association results for exonic SNPs correlated with the IGAP SNPs
Exonic SNP
IGAP SNP
Closest gene
SNP ID
Gene
OR
2
Strong LD (r ≥ 0.8)
rs6656401
CR1
rs4844600
CR1
rs2296160
CR1
1.11
rs9271192
HLA-DRB5
rs9270303
HLA-DRB1
1.16
rs1476679
ZCWPW1
rs2405442
PILRA
0.89
rs1859788
PILRA
0.89
rs9331896
CLU
rs7982
CLU
0.90
rs10838725
CELF1
rs2293576
SLC39A13
1.08
rs983392
MS4A6A
rs12453
MS4A6A
0.89
rs4147929
ABCA7
rs3752246
ABCA7
1.18
rs3865444
CD33
rs12459419
CD33
0.95
Moderate LD (0.4 ≤ r2 < 0.8)
rs9271192
HLA-DRB5

P-value
7.47 × 10-3
1.68 × 10-4
1.22 × 10-3
1.22 × 10-3
1.30 × 10-3
0.030
3.56 × 10-4
1.30 × 10-4
0.11

rs2308759
HLA-DRB1
1.09
0.062
rs1049092
HLA-DQB1
1.12
7.29 × 10-4
rs1049086
HLA-DQB1
1.11
1.37 × 10-3
rs2718058
NME8
rs2722372
NME8
0.90
3.19 × 10-3
rs2598044
NME8
0.90
3.61 × 10-3
rs1476679
ZCWPW1
rs909152
LRCH4
0.97
0.33
rs10838725
CELF1
rs12286721
AGBL2
1.05
0.13
rs983392
MS4A6A
rs7232
MS4A6A
0.87
3.53 × 10-5
rs8093731
DSG2
rs16961975
DSG3
1.21
0.23
rs61730311
DSG3
1.15
0.45
rs4147929
ABCA7
rs4147930
ABCA7
1.10
9.92 × 10-3
ABCA7
1.10
6.04 × 10-3
rs4147934
HMHA1
1.08
0.045
rs2074442
HMHA1
1.09
0.019
rs2074454
rs10404947
HMHA1
1.07
0.086
rs3865444
CD33
rs35112940
CD33
0.98
0.67
A bold p-value represents the statistical significance after FDR adjustment.
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide
polymorphism; ADSP = Alzheimer's Disease Sequencing Project; OR = odds ratio; LD=
linkage disequilibrium
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Table 3.5. Pathogenic nature of nonsynonymous single nucleotide polymorphism associated with AD
Major/minor
Exonic SNP
Gene
Variant a
SIFT
PolyPhen-2
allele
Nonsynonymous
rs2296160
CR1
G/A
A2419T
Tolerated (0.39)
Benign (0.0)
rs9270303
HLA-DRB1
C/T
A13T
Tolerated (1.0)
Benign (0.0)
rs1859788
PILRA
G/A
G78R
Tolerated (1.0)
Benign (0.0)
rs3752246
ABCA7
C/G
A1527G
Tolerated (0.88)
Benign (0.0)
rs7232
MS4A6A
T/A
T213S
Deleterious (0.03)
Possibly damaging (0.827)
a
The first amino acid is linked to major allele and the second one to minor allele, and the codon number is for the biggest isoform.
SNP = single nucleotide polymorphism

66

67

Table 3.6. Significant cis- and trans-association of the IGAP SNPs with blood gene expressions in ADNI
AD association
eQTL association
IGAP SNP
Closest gene Probe set ID a
Gene
Cis or trans
b
P-value c
β
P-value
11736388_a_at
TRIM4
Cis
rs1476679
ZCWPW1
-0.126
1.16 × 10-8
0.78
-7
11760665_at
ZKSCAN1
Cis
0.150
1.96 × 10
0.18
-17
11722909_a_at
GATS
Cis
0.177
4.14 × 10
0.86
11730247_a_at
PVRIG
Cis
0.088
8.39 × 10-5
0.36
-8
11743311_a_at
PILRB
Cis
-0.113
1.20 × 10
0.28
-8
11730023_s_at
PILRB
Cis
-0.106
3.44 × 10
0.53
-8
11730022_a_at
PILRB
Cis
-0.129
5.41 × 10
0.68
11755327_s_at LOC154761
Cis
rs11771145
EPHA1
0.110
5.11 × 10-6
0.59
-5
rs28834970
PTK2B
11761824_at
NSAP11
Trans
0.028
8.78 × 10
1.00
-5
11723344_at
TRIM35
Cis
-0.067
1.31 × 10
0.29
-15
11720981_a_at
PTK2B
Cis
0.109
3.03 × 10
0.13
-14
11720982_s_at
PTK2B
Cis
0.079
1.72 × 10
0.077
11720980_a_at
PTK2B
Cis
0.089
3.04 × 10-10
0.12
-7
rs10838725
CELF1
11725151_at
MYBPC3
Cis
0.145
1.82 × 10
3.80 × 10-4
rs983392
MS4A6A
11716846_a_at
MS4A6A
Cis
-0.087
1.27 × 10-12
0.045
-6
11732865_a_at
MS4A4A
Cis
-0.178
2.69 × 10
0.70
11751570_a_at
MS4A4A
Cis
-0.148
3.02 × 10-6
0.97
-6
rs8093731
DSG2
11735070_a_at
GNAL
Trans
-0.317
9.65 × 10
0.35
-5
rs7274581
CASS4
11720252_s_at
C20orf194
Trans
-0.210
7.33 × 10
0.74
-5
11723408_a_at
MKKS
Trans
-0.130
5.03 × 10
0.85
A bold p-value represents the statistical significance after FDR adjustment.
a
Probe set IDs on Affymetrix Human Genome U219 Array
b
P-values less than false discovery rate (FDR) adjusted significance level
c
P-values calculated by analysis of covariance with the outcome of gene expression and the predictor of AD status (normal/MCI/AD)
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; eQTL = expression quantitative trait
locus; ADNI = Alzheimer's Disease Neuroimaging Initiative

Table 3.7. Significant cis- and trans-association of the IGAP SNPs with brain gene expressions in NABEC and UKBEC
Closest
Gene
Cis or
Brain
SNP ID
Probe set ID a
β
P-value b
gene
expression
trans
region
NABEC
rs10792832 PICALM
ILMN_1714980
MRGPRD
Trans CRBLM
0.066 1.62 × 10-5
rs8093731
DSG2
ILMN_2380779
DLGAP1
Trans FCTX
0.848 4.87 × 10-10
ILMN_1783168
NETO1
Trans FCTX
0.757 1.66 × 10-6
ILMN_1780373
KCNG2
Trans CRBLM
0.408 6.76 × 10-5
rs7274581
CASS4
ILMN_1731948
PCK1
Trans CRBLM
0.241 7.29 × 10-6
UKBEC
rs6656401
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MEDU
0.152 3.50 × 10-6
MEDU
0.284 1.87 × 10-6
MEDU
0.183 1.15 × 10-5
MEDU
0.297 5.59 × 10-6
MEDU
0.323 9.83 × 10-6
AveALL
0.078 4.22 × 10-6
WHMT
0.172 6.55 × 10-7
a
Probe set IDs on HumanHT-12_v3 Expression BeadChips in NABEC, and on Affymetrix Exon 1.0 ST Arrays in UKBEC
b
P-values less than false discovery rate (FDR) adjusted significance level
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; NABEC = North American Brain
Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; FCTX = frontal cortex; CRBLM = cerebellum;
MEDU = medulla; WHMT = white matter; AveALL = average of all 10 regions
CR1

t2408244
t2434716
t2437801
t2376299
t2376457
t2377332

COL9A2
CERS2
ARHGEF2
CNTN2
CDK18
CR1,CR1L

Trans
Trans
Trans
Trans
Trans
Cis
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Table 3.8. Associations between gene expressions identified in NABEC and UKBEC and AD status in GSE5281 dataset, entorhinal
cortex (EC), hippocampus (HIPP), and medial temporal gyrus (MTG)
EC
HIP
MTG
Probe set ID a
β
P-value
β
P-value
β
P-value
b
Identified in NABEC
DLGAP1
206489_s_at
-0.979
0.058
-1.511
0.010
-1.383
0.03
206490_at
-0.320
0.31
-0.350
0.084
-1.266 1.04 × 10-3
210750_s_at
0.876
0.24
0.915
0.15
-0.348
0.56
-5
235527_at
-0.761
0.15
0.875 4.59 × 10
1.363
0.033
NETO1
1552736_a_at
-0.787
0.10
0.009
0.97
-1.140
0.058
1552904_at
-1.728 8.03 × 10-4
0.023
0.95
-1.400
0.027
1562713_a_at
-1.742
0.024
-0.614
0.41
-1.993 6.86 × 10-4
236440_at
-0.580
0.22
-0.744
0.064
-1.988 7.41 × 10-5
KCNG2
208550_x_at
-0.413
0.26
0.431
0.21
-1.933 6.97 × 10-4
PCK1
208383_s_at
0.948
0.20
0.787
0.26
1.306
0.030
A bold p-value represents the statistical significance after FDR adjustment.
a
Probe set IDs on Affymetrix U133 Plus 2.0 array
b
There is no MRGPRD expression data available.
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; EC = entorhinal
cortex; HIPP = hippocampus (HIPP); MTG = medial temporal gyrus

Table 3.8. (Continued)
Probe set ID a

β

EC
P-value

β

HIP
P-value

β

MTG
P-value
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Identified in UKBEC
COL9A2
213622_at
-0.384
0.32
0.502
0.37
1.031
0.021
-3
232542_at
1.696 7.83 × 10
0.148
0.76
-0.577
0.32
CERS2
222212_s_at
0.744 3.63 × 10-3
-0.526
0.11
0.480
0.021
ARHGEF2
1554783_s_at
-1.296
0.092
0.137
0.84
-0.942
0.17
207629_s_at
-0.319
0.52
-0.390
0.33
-0.373
0.33
209435_s_at
-0.920 1.79 × 10-6
0.246
0.16
0.058
0.77
235595_at
1.033
0.041
0.963
0.058
0.590
0.18
CNTN2
206970_at
-0.993
0.11
-1.725
0.020
-0.460
0.46
230045_at
0.751
0.023
-0.550
0.20
-0.146
0.58
CDK18
214797_s_at
-0.352
0.62
0.032
0.94
-0.152
0.78
CR1
206244_at
-0.783
0.24
-1.259
0.013
-2.028 2.29 × 10-3
208488_s_at
0.732
0.33
0.151
0.80
-0.231
0.69
217484_at
0.840
0.069
0.457
0.35
0.717
0.15
-3
244313_at
1.501 3.81 × 10
-0.099
0.86
-0.098
0.87
A bold p-value represents the statistical significance after FDR adjustment.
a
Probe set IDs on Affymetrix U133 Plus 2.0 array
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; EC = entorhinal
cortex; HIPP = hippocampus (HIPP); MTG = medial temporal gyrus
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Table 3.9. Associations between gene expressions identified in NABEC and UKBEC and AD status in GSE5281 dataset, posterior
cingulate (PC), superior frontal gyrus (SFG), and primary visual cortex (VCX)
PC
SFG
VCX
Probe set ID a
β
P-value
β
P-value
β
P-value
b
Identified in NABEC
DLGAP1
206489_s_at
-1.449
0.012
-1.801 3.57 × 10-4
-0.647
0.20
206490_at
-0.183
0.51
-1.229 3.20 × 10-3
-0.995
0.011
210750_s_at
1.027
0.094
-0.352
0.60
0.755
0.20
235527_at
-0.722
0.040
-0.671
0.16
-0.937
0.024
NETO1
1552736_a_at -0.098
0.74
-1.591 6.53 × 10-4
-0.556
0.29
1552904_at
-1.210
0.068
-0.740
0.061
-0.158
0.81
-3
1562713_a_at -1.180
0.13
-2.066 1.10 × 10
-0.557
0.16
236440_at
-1.029 5.19 × 10-3
-1.079
0.049
-0.404
0.29
KCNG2
208550_x_at
0.729
0.066
-1.089
0.024
0.965
0.017
PCK1
208383_s_at
0.906
0.28
-0.016
0.98
-0.470
0.48
A bold p-value represents the statistical significance after FDR adjustment.
a
Probe set IDs on Affymetrix U133 Plus 2.0 array
b
There is no MRGPRD expression data available.
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; PC = posterior
cingulate; SFG = superior frontal gyrus; VCX = primary visual cortex

Table 3.9. (Continued)
Probe set ID a

β

PC
P-value

β

SFG
P-value

β

VCX
P-value
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Identified in UKBEC
COL9A2
213622_at
-0.029
0.97
-0.142
0.73
0.734
0.034
232542_at
0.948
0.16
0.121
0.84
-0.537
0.22
CERS2
222212_s_at
-0.316
0.32
-0.275
0.33
0.567
0.031
ARHGEF2
1554783_s_at
0.910
0.21
-0.759
0.15
0.924
0.15
207629_s_at
0.185
0.69
-0.761
0.041
0.280
0.33
209435_s_at
0.461 3.20 × 10-4
-0.671
0.019
0.253
0.13
-3
235595_at
2.245 1.02 × 10
0.172
0.73
0.400
0.33
CNTN2
206970_at
-1.270
0.070
-1.402
0.011
0.284
0.56
230045_at
-0.104
0.72
-0.135
0.74
0.006
0.98
CDK18
214797_s_at
0.714
0.18
-0.899
0.12
0.796
0.18
CR1
206244_at
1.336
0.082
-1.075
0.10
1.282
0.049
208488_s_at
0.332
0.52
-1.239
0.015
0.655
0.20
217484_at
0.688
0.24
-0.344
0.45
1.139 4.21 × 10-3
244313_at
0.780
0.14
0.299
0.61
1.248
0.01
A bold p-value represents the statistical significance after FDR adjustment.
a
Probe set IDs on Affymetrix U133 Plus 2.0 array
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; PC = posterior
cingulate; SFG = superior frontal gyrus; VCX = primary visual cortex

Table 3.10. Associations between gene expressions identified in NABEC and UKBEC and AD status in Allen Institute dataset
FWM
HIP
PCx
TCx
Gene expression a
β
P-value
β
P-value
β
P-value
β
P-value
b
Identified in NABEC
DLGAP1
0.749
0.028
-0.109
0.056
-0.034
0.51
-0.036
0.38
NETO1
0.495
0.095
0.010
0.91
-0.033
0.55
-0.041
0.36
KCNG2
0.085
0.43
0.004
0.97
0.035
0.73
0.203
0.020
PCK1
0.380
0.25
0.248
0.36
0.533
0.04
0.368
0.096
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Identified in UKBEC
COL9A2
-0.262
0.12
0.016
0.88
0.062
0.62
0.232
0.041
CERS2
-0.087
0.55
0.094
0.11
-0.052
0.55
0.083
0.19
ARHGEF2
-0.088
0.27
-0.028
0.51
-0.021
0.59
0.112 1.98 × 10-3
CNTN2
-0.143
0.41
0.034
0.70
-0.086
0.42
0.219
0.011
CDK18
-0.218
0.22
0.063
0.53
0.059
0.59
0.263 2.41 × 10-3
CR1
0.151
0.46
0.128
0.47
0.005
0.97
0.045
0.78
A bold p-value represents the statistical significance after FDR adjustment.
a
RNA sequencing on Illumina HighSeq 2500
b
MRGPRD expression was removed because of little expressions.
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; FWM = white
matter; HIPP = hippocampus; PCx = parietal cortex; TCx = temporal cortex
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Figure 3.1. Possible causal relationships between single nucleotide polymorphisms (SNPs), mRNA, and phenotype.
IGAP = International Genomics of Alzheimer’s Project; eQTL = expression quantitative trait locus

Figure 3.2. Flow diagram of the subjects included in the analyses.
ADSP = Alzheimer's Disease Sequencing Project
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Figure 3.3. Correlation between gene expressions potentially regulated by IGAP SNPs in NABEC
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Figure 3.4. Correlation between gene expressions potentially regulated by CR1 SNPs in UKBEC

Figure 3.5. Plot for the associations of the CR1 SNPs with the CR1 expression in the
average of 10 brain regions of UKBEC. The outlined square, circle, and triangle indicate
the synonymous SNP rs4844600, the IGAP SNP rs6656401, and the nonsynonymous
SNP rs2296160, respectively.
SNP = single nucleotide polymorphism; ADSP = Alzheimer's Disease Sequencing
Project; UKBEC = United Kingdom Brain Expression Consortium
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CHAPTER FOUR
Identifying regions harboring Alzheimer’s disease related rare variants using scanstatistic-based analysis of exome sequencing data

Abstract
Recent advances in sequencing technologies have allowed the move toward
comprehensive genome-wide approaches, enabling more accurate genotyping of rare
variants. To date, several studies have succeeded in identifying rare variants associated
with Alzheimer’s disease (AD), yielding protective or risk effects. We applied a scanstatistic-based approach and developed an approach to construct optimized windows
within a gene to find meaningful clusters harboring risk or protective rare variants for
AD. Data in this study came from the Alzheimer's Disease Sequencing Project (ADSP)
comprising 18 studies from the Alzheimer's Disease Genetic Consortium (ADGC), and 6
studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium. Of the 10,031 subjects included in this study, 5,142 (51.3%)
were diagnosed as AD. We evaluated the scan statistics with different settings in TREM2
and TOMM40 as highly-replicated positive controls. We obtained very similar scan
statistic values when we specified the whole genome and chromosome as a large genetic
region. Our optimized window approach captured almost the entire gene in TREM2 and
the single variant in TOMM40 as a meaningful cluster. Applying the optimized window
approach in all genes, we detected clusters harboring risk or protective variants for AD
including MUC6, NXNL1, and BCAM. As more NGS data become available, it is of great
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interest to see whether these findings are replicated in other cohorts of European ancestry
as well as different populations.

Introduction
Over the past decade, genome-wide association studies (GWAS) have identified common
risk loci for Alzheimer’s disease (AD). It is well known that the ε4 allele of
apolipoprotein E (APOE) is the major genetic risk factor for late onset of AD. In addition
to APOE, GWAS have detected and replicated several single nucleotide polymorphisms
(SNPs) that are associated with susceptibility of AD, including in or close to CR1, BIN1,
INPP5D, MEF2C, CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2,
SLC24A4-RIN3, DSG2, CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33,
ZCWPW1, and CELF1 [41-45].

Rare variants have become a focus in the recent past. Although GWAS have been
successful in interrogating genetic variants for association with disease, GWAS are
performed under the “common disease – common variant” hypothesis positing that
common traits are caused by the combination of common variants with a small to
moderate effect [58]. GWAS rely on genotyping preselected SNPs and imputing
ungenotyped variants based on local linkage disequilibrium (LD) of a set of some
haplotypes from reference population. Imputation approaches have continually improved
and are quite accurate for common variants [59, 60] but are not as reliable for rare
variants [61]. Therefore, imputed rare variants are typically removed from GWAS
analysis. Although GWAS for common variants have revealed numerous susceptibility
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variants for common diseases, much of the genetic contribution to common diseases
remains unexplained – the so called ‘missing heritability’ problem [152, 153]. One
possible explanation of this missing heritability is that rare variants may account for
additional disease variability [153, 154].

Recent advances in sequencing technologies have allowed to move toward
comprehensive genome-wide approaches, enabling to accurately genotype rare variants
generally defined as a variant with minor allele frequency (MAF) < 1-5%. These nextgeneration sequencing (NGS) technologies have the potential to improve our
understanding the role of both common and rare variants in the underlying biological
mechanisms of developing a disease. Whole-exome sequencing (WES) and wholegenome sequencing (WGS) are ideal approaches to identify novel variants and genes
associated with complex traits.

To date, several studies have reported rare variants associated with AD, yielding
protective or risk effects. Jonsson et al. found that a rare missense variant in TREM2 -rs75932628 producing an amino acid substitution (arginine to histidine at codon 47) -was associated with the risk of AD [155]. Concurrently, Guerreiro et al. confirmed that
rs75932628 was the most associated variant with AD in TREM2 [156]. This variant is
considered the first NGS-based finding of a novel rare variant associated with AD risk.
Since then, several rare variants have been reported as risk or protective factors for AD,
including in or near BIN1, UNC5C, TREM2, CD2AP, AKAP9, EPHA1, SORL1, TM2D3,
PLCG2, ABI3, PLD3, and ABCA7 (Table 4.1).
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Most coding variants, however, are very rare, and thus an extremely large sample size is
required to identify a single variant associated with a disease. There are significant
computational and statistical challenges for these sequencing studies. Traditional singlevariant-based association tests are underpowered to detect rare variant associations unless
sample size and/or effect size is very large [62]. Instead of testing single variant
individually, more powerful and computationally efficient approaches for aggregating the
effects of rare variants have become a standard approach for association testing. Many
such approaches for testing association between rare variants within a pre-specified
region and a disease have been proposed. A recently-proposed scan-statistic-based test
can be used to detect the location of rare variant clusters influencing a disease. The scanstatistic-based test was introduced into human genetics by Hoh et al [65] to locate
susceptibility genes. Ionita-Laza et al. adapted this test to identify clusters of rare disease
risk variants based on a likelihood ratio under a Bernoulli model as proposed by
Kulldorff [66, 67].

Variants within a functional protein-coding domain may be located in close proximity
and may play a similar role in genetic mechanisms of a disease. Unlike association tests
or other cluster detection analyses, the scan-statistic-based test [67] adopted in this work
can both detect the location of clusters and examine the association against the null
hypothesis that variants within a certain scan window are equally likely to confer AD risk
compared to those outside the window. This approach is powerful when there are clusters
of disease-related variants with the same direction of association within a selected
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region/window [67]. In this study, we applied the scan-statistic-based approach and
optimized windows within a gene to find meaningful clusters harboring risk or protective
rare variants for AD.

Material and methods
Study subjects
Data in this study came from the Alzheimer's Disease Sequencing Project (ADSP)
comprising 18 studies from the Alzheimer's Disease Genetic Consortium (ADGC), and 6
studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium. The ADSP consists of a smaller family-based study and a casecontrol study of unrelated subjects. In this study, we used the case-control study dataset
containing whole exome sequencing (WES) data on 10,913 subjects (Table 4.2). Of the
10,913 subjects in WES data, 10,468 subjects who had the AD diagnosis available and
who were 65 years or older at the last visit or at death were included in a principal
component analysis (PCA) to identify ethnic outliers. PCA was performed in PLINK
v1.90a [82] using a linkage disequilibrium (LD) pruned subset of markers (pairwise r2 <
0.2) from these data and 1000 Genomes Project Phase 3 (1000 Genomes) [84] data after
removing symmetric SNPs and flipping SNPs discordant for DNA strands between
ADSP WES and 1000 Genomes data. We then plotted the first and second principal
components (PCs) for each individual (n = 10,468 from ADSP WES and n = 2,504 from
1000 Genomes) using the ggplot2 R package (version 2.2.0) [85] in R (version 3.4.1;
http://www.r-project.org). Based on the PC plot, 437 subjects were removed as ethnic

83

outliers (Figure 4.1 and Figure 4.2). We considered individuals who were marked as
prevalent or incident AD at year 0 AD cases.

ADSP WES data
We obtained the public access WES data containing biallelic single nucleotide variants
and insertion/deletion (indels) genotypes from ADSP in the unrelated sample set. The
WES data was generated by applying a quality control protocol designed by the ADSP
Quality Control Working Group, removing low-quality variants and samples (see the
details in Supplementary Method 1).

Statistical analysis
The likelihood ratio (LR) statistic for the Bernoulli model from the scan-statistic-based
test is defined as:

𝐿𝑅𝑊

𝑝̂ 𝑊 𝑦𝑊 1 − 𝑝̂ 𝑊 𝑛𝑊−𝑦𝑊 𝑞̂𝑊 𝑦𝐺−𝑦𝑊 1 − 𝑞̂𝑊 𝑛𝐺−𝑛𝑊−(𝑦𝐺 −𝑦𝑊)
( )
(
)
= {( 𝑟̂𝐺 ) ( 1 − 𝑟̂𝐺 )
𝑟̂𝐺
1 − 𝑟̂𝐺
1

if 𝑝̂ 𝑊 > 𝑞̂𝑊
otherwise

where
𝑦𝑊 = ∑ 𝑦𝑖 ,

𝑦𝐺 = ∑ 𝑦𝑖 ,

𝑖∈𝑊

𝑛𝑊 = ∑ 𝑛𝑖 ,

𝑖∈𝐺

𝑝̂ 𝑊 =

𝑦𝑊
,
𝑛𝑊

𝑞̂𝑊 =

𝑛𝐺 = ∑ 𝑛𝑖

𝑖∈𝑊

𝑦𝐺 − 𝑦𝑊
,
𝑛𝐺 − 𝑛𝑊

𝑖∈𝐺

𝑟̂𝐺 =

𝑦𝐺
𝑛𝐺

𝑊 is a window with fixed size 𝑤 defined by the number of base pairs, 𝐺 is a large genetic
region of interest, and 𝑦𝑖 and 𝑛𝑖 are the numbers of AD cases and total subjects carrying
the 𝑖th rare variant, respectively [67]. The window 𝑊 with the highest 𝐿𝑅𝑊 is the most
likely region to harbor a cluster of disease-associated variants.
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The definitions of the large genetic region 𝐺 and the window 𝑊 are flexible. The power
of the test primarily depends on the total number of risk variants in the entire genetic
region 𝐺, the expected number of risk variants in the cluster, and the ratio of the
probabilities of being risk variants inside and outside of the cluster [157]. Other factor
influencing the power is how well the scanning window size matches the true cluster size.
The scan statistics are sensitive for the chosen scanning window. A cluster within a 10 kb
sized region, for example, may not be detected by two consecutive scanning windows of
5 kb (i.e., the cluster is split by two windows). A sliding window approach (i.e., partially
overlapping windows) may be one of the solutions for this problem. Another issue is that
the power may decrease when the true cluster window size is larger relative to the entire
region and when scanning window size is too large compared to the true cluster size [67].
Ideally, one would hope to define a scanning window so that it is matched to the true
cluster harboring variants related to disease.

We first compared the likelihood ratio (LR) statistic between different settings for a large
genetic region 𝐺, a fixed window size 𝑊, and a sliding window size using a sliding
window approach. We used TREM2 (located on chromosome 6p21.1) and TOMM40
(located on chromosome 19q13.32) as highly-replicated positive controls to evaluate the
scan statistics for risk and protective effects. Using Fisher’s exact test as implemented in
PLINK v1.90a [82], we preliminarily confirmed that there was a significant variant in
each of TREM2 and TOMM40 based on the false discovery rate (FDR)-adjusted p-value
(i.e., q-value) < 0.05 defined as a significance level (Table 4.3). The variant rs75932628
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(R47H, position: 41,129,252) in TREM2 was a significant risk rare variant for AD,
showing a MAF of 0.94% in AD cases and 0.21% in controls. The odds ratio (OR) was
4.41 and p-value was 4.30 × 10-12. On the other hand, the variant rs1160983 (S183S,
position: 45,397,229) in TOMM40 had a protective effect with a MAF of 1.80% in AD
cases and 4.34% in controls (OR = 0.39 and p-value = 2.12 × 10-21). TOMM40 is close to
the APOE locus and the variant was in LD with APOE ε2 known as a protective factor (r2
= 0.35 and D’ = 0.95).

We tried to find optimized windows in TREM2 and TOMM40 by maximizing 𝐿𝑅𝑊 under
the difference genetic region 𝐺 settings. In addition to these positive control genes, we
applied the optimized window approach in all genes to identify regions that presumably
target AD associated loci (see the details in Supplementary Method 2). We then evaluated
the optimized windows using the burden test and sequence-kernel association test
(SKAT) for the optimized windows (Supplementary Method 3) [63, 64]. The SKAT is
powerful when both risk and protective variants are mixed and when a small proportion
of variants are causal, whereas the burden test is more powerful than SKAT when most of
the variants are causal and have the same direction of effect [63]. We used these
properties to confirm whether the optimized windows successfully captured a cluster
harboring risk or protective rare variants for AD.

In all analyses above, we assumed a dominant mode of inheritance (MOI), and defined a
rare variant as a variant of MAF < 0.05. We removed variants with a minor allele count
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(MAC) < 5. Variants were assigned to genes based on their physical positions at the
UCSC Genome Browser GRCh37/hg19 human assembly (https://genome.ucsc.edu/) [87].

Results
Of the 10,031 subjects included in this study, 5,142 (51.3%) were diagnosed as AD.
There were more females than males in both AD cases and controls. The majority of
controls were aged 80 years or older and had no APOE ε4 alleles (Table 4.4).

Scan-statistic-based analysis by a sliding window approach in TREM2 and TOMM40
Table 4.5 shows the log 𝐿𝑅𝑊 s for each window determined by a sliding window
approach with several different settings in TREM2 (risk effect) and TOMM40 (protective
effect). In both TREM2 and TOMM40, the log 𝐿𝑅𝑊 s were very similar when the large
genetic region 𝐺 was the whole genome or entire chromosome (6 and 19). When the large
genetic region 𝐺 was the band level (6p21.1 and 19q13.32), the log 𝐿𝑅𝑊 s were a little bit
smaller than those for the whole genome and entire chromosome specified as 𝐺. The
largest log 𝐿𝑅𝑊 (log 𝐿𝑅𝑊 ≈ 31) in TREM2 was obtained with the 5kb fixed and 2.5 kb
sliding window sizes (41,125,156 - 41,130,156) and the 10kb fixed and 5kb sliding
window sizes (41,120,156 - 41,130,156 and 41,125,156 - 41,135,156). From these
results, we expected that a meaningful cluster would exist in 41,125,156 - 41,130,156. On
the other hand, the setting with the 10kb fixed and 5kb sliding window sizes produced
less log 𝐿𝑅𝑊 than other two window settings in TOMM40, implying that an interesting
cluster would be in 45,395,468 - 45,397,468.
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Scan-statistic-based analysis by an optimized window approach in TREM2 and TOMM40
We optimized windows with each large genetic region 𝐺 in TREM2 and TOMM40 (Table
4.6). As expected above, we detected the optimized window 41,126,655 - 41,129,252 in
TREM2 existing within 41,125,156 - 41,130,156 and containing rs75932628 (R47H,
position: 41,129,252), whichever large genetic region 𝐺 was specified. In TOMM40, the
optimized window contained the associated single variant rs1160983 (S183S, position:
45,397,229) that was located within 45,395,468 - 45,397,468 detected by the sliding
window approach.

Genome-widely scan-statistic-based analysis by an optimized window approach
We applied the optimized window approach for all genes to identify clusters harboring
risk or protective variants associated with AD (Figure 4.3). Top 10 genes with large
log 𝐿𝑅𝑊 for each risk and protective effects were displayed in Table 4.7. Besides TREM2
and TOMM40, the optimized windows in MUC6, NXNL1, and BCAM had larger log 𝐿𝑅𝑊
than that in TREM2, and the optimized windows in MUC6, CADPS2, TYRO3, ADM,
BCAM, CBLC, and LNP1 captured the variants significantly associated with AD in the
single-variant-based analysis (Table 4.3). For MUC6, we detected two optimized
windows, one with a cluster of risk variants and the other with protective variants, both of
which had larger log 𝐿𝑅𝑊 than that in TREM2. The risk region 1,018,274 - 1,018,379
contained 4 risk variants including two significant variants rs202193006 (P1485S,
position: 1,018,348) and rs765785447 (A1474A, position: 1,018,379). Similarly, the
protective region 1,016,800 - 1,017,015 contained 9 protective variants including the
significant variant rs373231068 (P1971L, position: 1,016,889) (Table 4.8). For NXNL1,

88

the optimized window 17,565,477 - 17,566,489 were detected, harboring 4 risk rare
variants with relatively high effect sizes, although these variants did not reach the FDRadjusted significance level (Table 4.8). The optimized protective window 45,312,432 45,316,606 in BCAM was observed including two significant protective variants;
rs28399653 (R77H, position: 45,315,445) and rs28399654 (V196I, position: 45,316,588)
(Table 4.8).

Discussion
Based on the assumption that variants located in close proximity within a functional
protein-coding domain play a similar role in increased or decreased disease susceptibility,
we identified clusters of rare variants using the scan-statistic-based analysis with an
optimized window approach. First, we evaluated the scan statistics of TREM2 and
TOMM40 with different settings for a large genetic region 𝐺, a fixed window size 𝑊, and
a sliding window size by a sliding window approach. We obtained very similar log 𝐿𝑅𝑊
values when we specified the whole genome and chromosome as a large genetic region
𝐺. This may indicate that the scan statistics are comparable between windows in different
large genetic regions if the 𝐺 is large enough. Second, we optimized windows in the
scan-statistic-based analysis. Ideally, it would be the best that an optimized window
covers an entire gene if the gene itself affects a disease and captures one single variant if
only the variant within the gene is significant. Our optimized window approach
successfully identified the gene and the single variant in TREM2 and TOMM40,
respectively. Of the 9 variants existing in the TREM2 gene region in the analysis, 8
variants were contained in the optimized window. In addition, the p-value from the
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burden test was smaller than that from SKAT as shown in Table 4.7. These may indicate
that this optimized window successfully captured variants with the same direction of
effect, and the entire TREM2 gene is associated with AD susceptibility as consistent to
the previous report [158]. On the other hand, only one protective variant in TOMM40 was
identified by the optimized window approach. There existed 3 variants in the TOMM40
gene region. One was insignificant (OR = 0.71 and p-value = 0.71) and the other was
rather risk (OR = 8.1 and p-value = 7.70 × 10-4).

Applying the optimized window approach in all genes, we detected two regions in
MUC6; 1,018,274 - 1,018,379 with a risk effect and 1,016,800 - 1,017,015 with a
protective effect, both of which were larger log 𝐿𝑅𝑊 than TREM2. That is, risk and
protective clusters coexist in MUC6. If a region has heterogeneity effect (i.e., including
both risk and protective variant), the sliding window approach may not be able to detect
regions unless proper window sizes are specified. The optimized window approach
demonstrated that there exists two interesting regions in MUC6; one with a cluster of risk
variants including two significant variants and the other with protective variants
including one significant variant. The optimized window approach also detected the
cluster in NXNL1 that captured 4 adjacent risk variants which are in strong LD with each
other (r2 = 0.87 to 0.98 and D’ = 0.99 to 1). Although these variants were not shown to be
significantly associated with AD in the single-variant-based test, the log 𝐿𝑅𝑊 of the
optimized region was larger than that in TREM2, indicating that there is a cluster of
disease risk variants within this region. The optimized window in BCAM was relatively
large (the length was about 4kb) that captured 9 variants including two significant
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protective variants. BCAM is located close to the APOE locus. The pairwise LD values
were r2 = 0.09 and D’ = 0.46 between two significant protective variants and APOE ε2.
Thus, the protective effect of BCAM may come from the APOE ε2 protective impact on
AD as well as TOMM40.

In recent years, the importance of TREM2 has been highlighted due to increased risk for
AD. Consistent with previous studies [155, 156, 159, 160], the missense variant
rs75932628 (R47H) in TREM2 was detected as a risk variant of AD in the single-variantbased analysis. TREM2 located on chromosome 6p21.1 encodes a transmembrane
receptor primarily expressed in microglia [161, 162], and has been shown to suppress
inflammatory responses [163]. We optimized a window in which there were 8 risk
variants with a relatively large effect size, all of which were missense variants except
rs144250872 (L133L). The two variants rs2234253 (T96K) and rs2234256 (L211P) were
in perfect LD with each other. The variant rs2234255 (H157Y) had the largest estimated
OR (OR = 10.48, p-value = 6.50×10-3), showing a MAF of 0.11% in AD cases and 0.01%
in controls.

The association of rs75932628 (R47H) was replicated in many studies for individuals of
European ancestry [158, 164-167], while other studies failed to replicate this association
in East Asian and African American populations [168-171]. The association of the
variant rs2234255 (H157Y) was found in the study of the Han Chinese [172] but not of
European populations so far. Also, the variant rs2234256 (L211P) was identified in
African American [171]. These disparities may be raised because of high variabilities of
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MAF in the rare variants among different populations. According to Exome Aggregation
Consortium (ExAC) data, for example, the MAFs are 0.26% in European, 0.088% in
African American, and 0% in East Asian for rs75932628 (R47H), 0.0030% in European,
0.059% in African American, and 0.20% in East Asian for rs2234255 (H157Y), and
0.096% in European, 12.8% in African American, and 0.15% in East Asian for
rs2234256 (L211P) [173]. Since we extracted individuals of European ancestry based on
PCs in this study, there may not be enough power to detect rs2234255 (H157Y) in the
single-variant-based analysis, although the effect size was large. We did identify the
genetic region (i.e., 41,126,655 - 41,129,252) using the scan-statistic-based analysis with
an optimized window approach in which potential risk variants previously identified
across various populations were harbored.

Using the large WES dataset derived from multiple research centers, we demonstrated the
practicability of the optimized window approach in the scan-statistic-based analysis to
detect a single variant and a cluster harboring risk or protective variants for AD. We
identified several candidate genes exhibiting risk for AD and others playing a protective
role using the optimized window approach. Our results strongly suggest the need for
more investigation for these novel genes. As more NGS data become available, it is of
great interest to see whether these findings are replicated in other cohorts of European
ancestry as well as different populations. We also plan in future studies to examine how
these mutations change the protein structure and function, and/or whether transgenic mice
with these mutations exhibit AD-related pathogenesis.
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Table 4.1. Summary of the major findings in rare variants associated with late-onset
Alzheimer’s disease
Gene
Chr
SNV
Position
Variant
Reference
BIN1
2 rs138047593
127,808,046
K358R
[174]
UNC5C
4 rs137875858
96,091,431
T835M
[175]
TREM2
6 rs143332484
41,129,207
R62H
[158, 176]
rs75932628
41,129,252
R47H
[155, 156]
CD2AP
6 rs116754410
47,591,941
K633R
[174]
AKAP9
7 rs144662445
91,709,085
I2546M
[177]
rs149979685
91,732,110
S3767L
[177]
EPHA1
7 rs202178565
143,095,499
P460L
[174]
SORL1
11 rs117260922
121,367,627
E270K
[178]
rs143571823
121,429,476
T947M
[178]
TM2D3
15 rs139709573
102,186,966
P155L
[179]
PLCG2
16 rs72824905
81,942,028
P522R
[176]
ABI3
17 rs616338
47,297,297
S209F
[176]
PLD3
19 rs145999145
40,877,595
V232M
[180]
ABCA7
19 rs72973581
1,043,103
G215S
[74]
rs770510230
1,058,154
E1679X
[174]
Chr = chromosome; SNV = single nucleotide variant
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Table 4.2. Number of cases/controls and age range in each case-control study of ADSP
Consortium Study
Cases
Controls
n
Age range
n
Age range
ADGC
4,966
40-99+
3,209
42-99+
ACT
273
69-89
996
68-89
ADC
2,417
60-90+
839
64-90+
CHAP
27
68-90+
204
78-90+
EFIGA
160
59-90+
171
42-90+
GDF
111
59-90+
96
77-90+
NIA-LOAD
364
37-90+
111
78-90+
MAP
132
71-90+
283
72-90+
MAYO
250
60-87
99
78-90+
MAYO PD
181
59-89
14
79-90+
MIA
316
56-88
15
78-89
MIRAGE
0
20
74-90+
NCRAD
160
58-90+
0
RAS
46
56-88
0
ROS
144
63-90+
207
67-90+
TARCC
132
60-90+
12
80-89
TOR
9
40-84
0
VAN
210
60-90+
26
79-90+
WHICAP
34
73-90+
116
78-90+
CHARGE

805
60-99+
1,927
61-99+
ARIC
39
67-89
18
77-85
ASPS
121
60-89
5
78-86
CHS
251
68-90+
583
76-90+
ERF
45
60-88
0
FHS
126
65-90+
455
61-90+
RS
223
61-90+
866
76-90+
ADSP = Alzheimer's Disease Sequencing Project; ACT =Adult Changes in Thought;
ADC = NIA Alzheimer Disease Centers; CHAP = Chicago Health and Aging Project;
EFIGA = Estudio Familiar de la Influencia Genetica en Alzheimer; GDF = Genetic
Differences; NIA-LOAD = National Institute on Aging (NIA) Late Onset Alzheimer's
Disease Family Study; MAP = Memory and Aging Project; MAYO = Mayo Clinic;
MAYO PD = Mayo PD; MIA = University of Miami; MIRAGE = Multi-Institutional
Research in Alzheimer's Genetic Epidemiology; NCRAD = National Cell Repository for
Alzheimer's Disease; RAS = University of Washington Families; ROS = Religious
Orders Study; TARCC = Texas Alzheimer's Research and Care Consortium; TOR =
University of Toronto; VAN = Vanderbilt University; WHICAP = Washington HeightsInwood Columbia Aging Project; ARIC = Atherosclerosis Risk in Communities Study;
ASPS = Austrian Stroke Prevention Study; CHS = Cardiovascular Health Study; ERF =
Erasmus Rucphen Family; FHS = Framingham Heart Study; RS = Rotterdam Study
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Table 4.3. Significantly associated rare coding variants with Alzheimer’s disease assuming a dominant mode of inheritance
No. of subjects
MAF (%)
with minor allele
Chr
SNV ID
Position
Gene
Alleles a
OR
P-value b
Variant
Cases Controls
Cases Controls
3 rs9844083
100,170,628
LNP1
A/G
0.33
0.97
28
76
0.33
1.59×10-7
Q74Q
-12
6 rs75932628
41,129,252 TREM2
C/T
0.94
0.21
96
21
4.41 4.30×10
R47H
7 rs746999306 122,303,575 CADPS2
A/C
0.35
0.03
35
3 11.31
7.49×10-8
C168G
11 rs373231068
1,016,889
MUC6
G/A
2.26
4.73
194
380
0.45 4.97×10-19
P1971L
-16
11 rs202193006
1,018,348
MUC6
G/A
4.38
2.29
434
219
2.00 1.16×10
P1485S
-13
11 rs765785447
1,018,379
MUC6
G/C
3.59
1.90
359
182
1.96 1.41×10
A1474A
11 rs764691516
10,327,875
ADM
G/C
0.97
0.32
87
29
3.08
3.10×10-8
R14P
-8
15 rs149022093
41,862,356 TYRO3
T/C
2.25
1.12
188
92
2.05
1.18×10
1382+2T>C
-8
19 rs3208856
45,296,806
CBLC
C/T
2.68
4.15
272
392
0.64
3.35×10
H405Y
-8
19 rs28399653
45,315,445
BCAM
G/A
2.47
3.90
249
369
0.62
1.45×10
R77H
19 rs28399654
45,316,588
BCAM
G/A
2.45
4.02
248
383
0.60 5.75×10-10
V196I
19 rs1160983
45,397,229 TOMM40
G/A
1.80
4.34
140
340
0.39 2.12×10-21
S183S
a
Major/minor alleles
b
P-values were calculated by Fisher’s exact test and displayed if significant based on false discovery rate (FDR) adjusted p-value <
0.05.
Chr = chromosome; SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio

Table 4.4. Characteristics of ADSP study subjects (n = 10,031)
AD cases (n = 5,142)
AD controls (n = 4,889)
Variable
n
%
n
%
Sex
Male
2,226
43.3
1,995
40.8
Female
2,916
56.7
2,894
59.2
Age a
65 - 69
506
9.8
12
0.2
70 - 74
1,008
19.6
29
0.6
75 - 79
1,105
21.5
169
3.5
80 - 84
1,041
20.2
1,510
30.9
85 - 89
866
16.8
2,197
55.9
90 +
616
12.0
972
19.9
APOE
-/3,001
58.4
4,189
85.7
ε4 / 2,068
40.2
683
14.0
ε4 / ε4
73
1.4
17
0.3
a
Age at the last visit or at death
ADSP = Alzheimer's Disease Sequencing Project
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Table 4.5. Scan-statistic (logLRw) for windows determined by a sliding window approach in several different settings, TREM2 and
TOMM40
Window size
Window position
Gene
G
logLRw
Fixed Sliding
Start
End
Risk effect
TREM2
2kb
1kb
41,128,156 41,130,156
Genome
25.42
Chromosome 6
25.43
Band 6p21.1
24.19
41,129,156 41,131,156
Genome
20.27
Chromosome 6
20.27
Band 6p21.1
19.24
5kb
2.5kb
41,125,156 41,130,156
Genome
31.02
Chromosome 6
31.03
Band 6p21.1
29.57
41,127,656 41,132,656
Genome
25.42
Chromosome 6
25.43
Band 6p21.1
24.19
10kb
5kb
41,120,156 41,130,156
Genome
31.01
Chromosome 6
31.02
Band 6p21.1
29.55
41,125,156 41,135,156
Genome
31.02
Chromosome 6
31.03
Band 6p21.1
29.57
logLRw = log likelihood ratio for the window

Table 4.5. (Continued)
Window size
Gene
Fixed Sliding
Protective effect
TOMM40
2kb
1kb

5kb

2.5kb

Window position
Start
End
45,397,468

45,396,468

45,398,468

45,393,968

45,398,968

45,396,468

45,401,468

45,391,468

45,401,468

45,396,468

45,406,468
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45,395,468

10kb

5kb

logLRw = log likelihood ratio for the window

G
Genome
Chromosome 19
Band 19q13.32
Genome
Chromosome 19
Band 19q13.32
Genome
Chromosome 19
Band 19q13.32
Genome
Chromosome 19
Band 19q13.32
Genome
Chromosome 19
Band 19q13.32
Genome
Chromosome 19
Band 19q13.32

logLRw
48.43
48.13
44.85
48.43
48.13
44.85
48.43
48.13
44.85
48.43
48.13
44.85
38.37
38.06
34.64
40.10
39.82
36.74

Table 4.6. Scan-statistic (logLRw) for windows determined by an optimized window
approach in each large genetic region, TREM2 and TOMM40
Optimized window
Gene
G
logLRw
Start
End
Risk effect
TREM2
41,126,655
41,129,252
Genome
31.19
41,126,655
41,129,252
Chromosome 6
31.20
41,126,655
41,129,252
Band 6p21.1
29.75
Protective effect
TOMM40
45,397,229
45,397,229
Genome
48.43
45,397,229
45,397,229 Chromosome 19
48.13
45,397,229
45,397,229
Band 19q13.32
44.85
logLRw = log likelihood ratio for the window
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Table 4.7. Optimized windows for top 10 genes with a large scan-statistic in risk and protective effects
Optimized window
Optimized window
No. of
p-value a
Chr
Gene
logLRw
subjects
Start
End
SKAT
Burden
Risk effect
11
1,018,274
1,018,379
MUC6
56.19
1.16×10-16 9.05×10-17
9,664
19
17,566,477
17,566,489
NXNL1
45.88
7.39×10-7
7.20×10-7
7,679
-11
-14
6
41,126,655
41,129,252
TREM2
31.19
2.55×10
7.22×10
9,801
7 149,482,580 149,520,553
SSPO
0.18
0.30
2,369
21.19
b
4 190,903,822 190,903,880 TUBB4Q
0.045
0.072
9,175
18.59
17
5.18×10-4
4.51×10-4
9,829
18,907,029
18,923,180 SLC5A10
17.21
-3
-3
14
ABCD4
8.48×10
8.48×10
10,029
74,763,064
74,766,360
16.16
-7
-7
7 122,303,575 122,303,598 CADPS2
16.09
1.93×10
1.11×10
9,825
-10
-8
15
41,862,356
41,862,520
TYRO3
14.48
8.12×10
1.81×10
8,243
11
10,327,875
10,327,875
ADM
13.68
3.10×10-8 c
9,020

No. of
variants in
the window
4
4
8
137
9
8
4
2
3
1

Protective effect
1,016,800
1,017,015
MUC6
1.14×10-12 2.00×10-10
6,933
9
11
51.62
2.12×10-21 c
1
19
45,397,229
45,397,229 TOMM40
48.43
7,978
-8
-8
1.89×10
1.00×10
8,909
9
19
45,312,432
45,316,606
BCAM
34.95
-5
-6
2.66×10
4.47×10
9,457
6
19
45,296,767
45,297,479
CBLC
24.83
-4
-5
55,594,868
55,595,291
OR5L2
1.98×10
9.39×10
9,655
7
11
22.98
2.19×10-3
1.02×10-3
9,561
4
2
89,246,948
89,246,978 IGKV1-5
16.31
-5
-5
6.38×10
2.65×10
9,774
3
19
55,179,184
55,179,217
LILRB4
16.29
0.11
0.17
6,702
55
6
30,954,438
30,955,218
MUC21
15.71
-7
-6
LNP1
2.11×10
1.02×10
7,798
2
3 100,170,589 100,170,628
14.92
CDKL1
1.71×10-4
9.19×10-3
7,995
15
14
50,799,018
50,857,010
14.61
a
P-values obtained from the subjects with no missing variants; b Pseudogene; c P-values were calculated by Fisher’s exact test
logLRw = log likelihood ratio for the window; SKAT = sequence-kernel association test; Burden = the burden test

Table 4.8. Single-variant-based association within the optimized windows
SNV ID

Position

Alleles

a

MAF (%)
Cases

Risk effect
11: 1,018,274 - 1,018,379 (MUC6)
rs79073076
1,018,274
rs200240449
1,018,334
1,018,348
rs202193006
1,018,379
rs765785447

Controls

No. of subjects
with minor allele
Cases Controls

OR

P-value b

Variant
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G/C
C/T
G/A
G/C

0.04
0.27
4.38
3.59

0.01
0.19
2.29
1.90

4
27
434
359

1
19
219
182

3.81
1.35
2.00
1.96

0.38
0.38
1.16×10-16
1.41×10-13

T1509T
T1489T
P1485S
A1474A

19: 17,566,477 - 17,566,489 (NXNL1)
rs773959663
17,566,477
G/C
rs761407534
17,566,481
T/C
rs767189869
17,566,484
T/C
rs750720749
17,566,489
A/C

1.02
0.93
0.75
0.86

0.38
0.33
0.27
0.28

88
80
71
68

32
28
23
23

2.73
2.84
2.84
3.10

4.41×10-7
5.46×10-7
6.43×10-7
6.58×10-6

G206G
E205G
E204G
G203G

6: 41,126,655 - 41,129,252 (TREM2)
rs2234256
41,126,655
A/G
0.21
0.09
22
9
2.33
0.031
L211P
-3
rs2234255
41,127,543
G/A
0.11
0.01
11
1 10.48
6.50×10
H157Y
rs144250872
41,127,613
C/A
0.16
0.10
17
10
1.61
0.25
L133L
rs145080901
41,129,078
G/A
0.04
0.02
4
2
1.90
0.69
A105V
rs2234253
41,129,105
G/T
0.21
0.09
22
9
2.33
0.031
T96K
rs142232675
41,129,133
C/T
0.21
0.09
22
9
2.33
0.031
D87N
-3
rs143332484
41,129,207
C/T
1.35
0.90
137
87
1.51
2.88×10
R62H
41,129,252
C/T
0.94
0.21
96
21
4.41 4.30×10-12
R47H
rs75932628
A bold SNV and p-value represent the significant variants based on the false discovery rate (FDR)-adjusted significance level.
a
Major/minor alleles, b P-values were calculated by Fisher’s exact test.
SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio

Table 4.8. (Continued)
SNV ID

Position

Alleles

a

MAF (%)
Cases
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Protective effect
11: 1,016,800 - 1,017,015 (MUC6)
rs199626069
1,016,800
rs761958882
1,016,801
rs756062369
1,016,809
rs747778866
1,016,818
rs762086454
1,016,835
rs76307106
1,016,870
1,016,889
rs373231068
rs200695483
1,016,957
rs767697427
1,017,015

G/A
G/C
G/T
A/G
A/G
G/A
G/A
T/C
T/G

0.04
0.03
0.04
0.54
0.50
0.10
2.26
0.03
0.02

Controls

0.07
0.06
0.07
0.97
1.02
0.11
4.73
0.03
0.06

No. of subjects
with minor allele
Cases Controls

4
3
4
55
51
10
194
3
2

7
6
7
93
98
10
380
3
6

OR

0.54
0.48
0.54
0.56
0.49
0.94
0.45
0.94
0.32

P-value b

Variant

0.38
0.33
0.38
6.33×10-4
3.09×10-5
1
-19
4.97×10
1
0.17

P2001S
H2000Q
P1998T
Y1995H
F1989S
P1977P
P1971L
R1948R
E1929A

19: 45,312,432 - 45,316,606 (BCAM)
rs767090237
45,312,432
G/A
0.02
0.05
2
4
0.47
0.44
L17L
rs573141230
45,314,496 GTGCGCT/G
0.08
0.14
8
13
0.58
0.28 R34_L35del
45,315,445
G/A
2.47
3.90
249
369
0.62
R77H
rs28399653
1.45×10-8
rs3745159
45,315,539
G/A
0.22
0.30
23
29
0.75
0.33
G108G
rs144124876
45,315,573
G/A
0.03
0.02
3
2
1.43
1.00
E120K
rs200398713
45,315,656
T/A
0.10
0.06
10
6
1.59
0.46 433+8T>A
rs143018179
45,315,799
C/G
0.22
0.32
23
31
0.70
0.22
A166A
-10
45,316,588
G/A
2.45
4.02
248
383
0.60 5.75×10
V196I
rs28399654
rs776849980
45,316,606
G/A
0.02
0.07
2
7
0.27
0.10 601+3G>A
A bold SNV and p-value represent the significant variants based on the false discovery rate (FDR)-adjusted significance level.
a
Major/minor alleles, b P-values were calculated by Fisher’s exact test.
SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio

Figure 4.1. Flow diagram of the subjects included in the analyses.
WES = Whole-exome sequencing; ADSP = Alzheimer's Disease Sequencing Project
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Figure 4.2. First and second principal components plots along with 1000 genome
reference samples. Block dots indicate individuals in this study. We chose individuals
within the red dotted circle based on Euclidean distance.
AFR = African; AMR = Admixed American; EAS = East Asian; EUR = European; SAS
= South Asian
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Figure 4.3. Manhattan plot of scan-statistic (logLRw) for the optimized windows in each gene.

Supplementary Method 1
Quality control (QC) was performed for each of the variant call formats (VCFs) received
from two institutions; the Human Genome Sequencing Center at Baylor College of
Medicine (hereafter, Baylor) in which genotype calling was conducted using Atlas V2
software [181] and the Broad Institute (hereafter, Broad) in which genotype calling was
conducted using Genome Analysis Toolkit (GATK)-HaplotypeCaller [182]. Both of the
VCFs were derived from the same set of BAM file.

Primary QC
Distinct primary QCs were applied to each of the sets of VCFs due to differences in the
calling pipelines. For the Broad VCFs, variants that did not have a “PASS” in the
FILTER field were deleted. For the Baylor VCFs, variants with a low mapping score and
genotypes that did not have a “PASS”, that had a low read depth, or that had an out-ofrange variant read to total read depth ratio were deleted. Then, monomorphic variants,
variants with high missing rate (≥ 20%), variants with high read depth (> 500 reads), or
variants (only for MAF > 0.001) with Hardy-Weinberg equilibrium p-value < 5×10-6
were deleted.

Concordance check between the Baylor and Broad VCFs
Variants were compared between the QCed VCFs. The consensus protocol was defined
as follows.
(1) Variants in which a different alternative allele was called between the two VCFs
were excluded.
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(2) All genotypes in remaining variants that were concordant between the two QCed sets
of VCFs were included in the final consensus set.
(3) All genotypes that were discordant between the two QCed sets of VCFs were set to
missing.
(4) All genotypes that were present only in the QCed Baylor VCF (but were missing in
the QCed Broad VCF) were included in the final consensus set.
(5) Genotypes that were present only in the QCed Broad VCF (but were missing in the
QCed Baylor VCF) that met a GQ threshold were included in the final consensus set.
i.

The genotype quality score (GQ) threshold was set to the 0.1 percentile
(genotype-specific) based on genome-wide comparisons of WES and GWAS
genotypes.

ii.

Genotypes from the Broad VCF that were not present in the Baylor VCF
were excluded if they had GQ values less than 21 for “0/0” genotypes, less
than 85 for “0/1” genotypes or less than 36 for “1/1” genotypes.

Second round of variant level QC
After the consensus genotypes were determined, the same QC protocol as the primary QC
was applied.
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Supplementary Method 2
In order to optimize a window for a genetic region of interest 𝐺 (e.g., chromosome), we
modified the sliding window approach as follows.

1. We specified a large base genetic region 𝐺 and a window of interest 𝑊 to get it to
be optimized.
2. A total of 𝑀 variants in 𝐺 were sorted in an ascending order based on the physical
position.
3. We set the 𝑗th window as 𝑤𝑗 containing 𝑚𝑗 variants (𝑚𝑗 < 𝑀). We denoted the
physical position of the 𝑖th variant as 𝑝𝑖 with 𝑖 = 1, … , 𝑚𝑗 .
𝑓

4. We then calculated forward log 𝐿𝑅𝑊𝑖𝑗 for each window from 𝑝1 to 𝑝𝑖 with 𝑖 =
𝑓

1, … , 𝑚𝑗 , and obtained arg max log 𝐿𝑅𝑊𝑖𝑗 .
𝑝𝑖

𝑏
5. We set the end position of window as 𝑝𝑚𝑗 and calculated backward log 𝐿𝑅𝑊
for
𝑖𝑗
𝑏
each window from 𝑝𝑖 to 𝑝𝑚𝑗 with 𝑖 = 2, … , 𝑚𝑗 , and obtained arg max log 𝐿𝑅𝑊
.
𝑖𝑗
𝑝𝑖

𝑓

𝑏
6. We compared between max log 𝐿𝑅𝑊𝑖𝑗 and max log 𝐿𝑅𝑊
.
𝑖𝑗
𝑓

𝑓

𝑏
If max log 𝐿𝑅𝑊𝑖𝑗 > max log 𝐿𝑅𝑊
, we set log 𝐿𝑅𝑊𝑗 = max log 𝐿𝑅𝑊𝑖𝑗 ,
𝑖𝑗
𝑏
otherwise, log 𝐿𝑅𝑊𝑗 = max log 𝐿𝑅𝑊
.
𝑖𝑗

7. We compared log 𝐿𝑅𝑊𝑗−1 and log 𝐿𝑅𝑊𝑗 .
If log 𝐿𝑅𝑊𝑗 ≤ log 𝐿𝑅𝑊𝑗−1 , we stopped and obtained log 𝐿𝑅𝑊𝑗 and the
window as an optimized window so that the length 𝑊𝑗 was minimized.
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Otherwise, we repeated 3 to 7 until we obtained the maximum value of
log 𝐿𝑅𝑊 and its window positions.
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Supplementary Method 3 [63, 64]
The SKAT aggregates score test statistics assuming that regression coefficient 𝛽𝑗 for the
𝑗th variant follows an arbitrary distribution with mean 0 and variance 𝑤𝑗2 𝜓, where 𝑤𝑗 is a
weight that depends on MAF. The SKAT test statistic is expressed as
𝑚

𝑚

2

𝑛

𝑄𝑆 = ∑ 𝑤𝑗2 𝑆𝑗2 = ∑ 𝑤𝑗2 {∑ 𝑔𝑖𝑗 (𝑦𝑖 − 𝑝̂ 𝑖,0 )}
𝑗=1

𝑗=1

𝑖=1

where 𝑔𝑖𝑗 is a genotype of the 𝑗th variant for the 𝑖th subject (𝑔𝑖𝑗 = 0, 1, or 2), and 𝑝̂ 𝑖,0 is
a estimated probability of the phenotype under the null logistic regression model. The test
hypothesis 𝐻0 : 𝜷 = 0 is equivalent to the hypothesis 𝐻0 : 𝜓 = 0. Instead of summing up
the square of weighted score test statistics, the burden test treats the square of the sum of
weighed score test statistics defined as
𝑚

2

𝑚

𝑛

2

𝑄𝐵 = (∑ 𝑤𝑗 𝑆𝑗 ) = {∑ 𝑤𝑗 ∑ 𝑔𝑖𝑗 (𝑦𝑖 − 𝑝̂𝑖,0 )}
𝑗=1

𝑗=1

𝑖=1

The SKAT is powerful when both risk and protective variants are mixed, and when a
small proportion of variants are causal, whereas the burden test is more powerful than
SKAT when most of the variants are causal and have the same direction of effect [63].
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CHAPTER FIVE
Conclusion

Summary
Dementia is a complex condition caused by a number of diseases each with an interplay
of genetic and environmental factors. With the advance of molecular genetic
technologies, studies have been performed in search of genes influencing dementia
susceptibility. GWAS have identified many genetic loci that contribute to dementia.
However, most of the loci have moderate to small estimated effects, often making it
difficult to reproduce in experimental work such as transgenic mouse models. Ideally, we
would perform global analyses including information from DNA sequence to levels of
proteins and metabolites, which is deemed “systems genetics” [121, 123]. Genetic data
from GWAS can play a part of the role of systems genetics by demonstrating interactions
among genes and between gene and gene expression by utilizing eQTL mapping. Recent
sequencing technologies have allowed us not only to increase our resolution of genetic
associations but also to integrate information for a multi-omics/systems genetics
approach that includes genomics, epigenomics, transcriptomics, proteomics,
metabolomics, and microbiomics [183, 184].

Disease associated genetic variants have the potential to be a powerful anchor point for
unidirectional flow in disease causal networks, in which the genetic variants affect
downstream layers (i.e., the levels of transcripts, proteins and metabolites). Integrating
omics layer data with genomic data can help to identify causal SNPs and genes/regions
and to examine causal pathways leading to disease. The purpose of this dissertation
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research was to identify SNPs and genes/regions that are potentially causal for dementia,
especially focusing on HS-Aging and AD using genomic and transcript data. Genomic
and transcript data were used to conduct three studies: (1) Gene-based association study
of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B,
ABCC9, and KCNMB2, (2) Translating Alzheimer’s disease risk polymorphisms into
functional candidates: a survey of IGAP genes, and (3) Identifying regions harboring
Alzheimer’s disease related rare variants using scan- statistic-based analysis of exome
sequencing data. The major findings from each of these studies are summarized below.

In the first study, we examined the genetic associations of four candidate genes (GRN,
TMEM106B, ABCC9, and KCNMB2) for HS-Aging pathology using the large autopsy
dataset derived from multiple research centers. The important findings are that the
significant gene-based association between ABCC9 and HS-Aging appeared to be driven
by a region in which a significant haplotype-based association was found, and that the
protective haplotype was associated with down-regulation of the ABCC9 expression in
two independent datasets. The association between ABCC9 and other dementias has
never been reported. That is, ABCC9 could potentially be a key gene that distinguishes
HS-Aging from other types of dementia.

The ABCC9 gene encodes a transmembrane protein, a part of an ATP-sensitive potassium
(KATP) channel complex. KATP channels are widely expressed in various brain regions
including hippocampus [100, 185]. This channel consists of two distinct subunits: an
inwardly rectifying K+ channel (Kir6.x) and a regulatory sulfonylurea receptor (SURx)
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[98]. Two alternatively spliced isoforms of SUR2 (i.e., SUR2A and SUR2B) are encoded
by ABCC9 differing only in the last 42 C-terminal amino acid residues [100, 186, 187].
KATP channels are formed by the combination of Kir6.x and SURx in different tissues;
Kir6.2/SUR1 in pancreatic β-cells and brain, Kir6.2/SUR2A in heart and skeletal muscle,
Kir6.2/SUR2B in smooth muscle and brain, and Kir6.1/SUR2B in vascular smooth
muscle [99, 186]. KATP channels are important for neuroprotection against brain injury.
When the ATP levels drop due to hypoxia/ischemia, vascular smooth muscle cell KATP
channels open to increase K+ efflux, voltage-activated calcium channels close to block
Ca2+ entry, and in turn, vasodilatation is induced for limiting tissue damage [99, 100].
Given the critical roles in regulation of vascular tone, KATP channel dysfunction may be
involved in cardiovascular-related diseases. Leverenz et al. showed that HS-Aging cases
were more likely to have history of stroke, small vessel disease, and hypertension than
AD cases [47]. Neltner et al. reported that brains with HS-Aging pathology tended to
have arteriolosclerosis in multiple cortical and subcortical regions [103]. Therefore,
cerebrovascular factors might be involved in developing HS-Aging via the KATP channeldependent activity [105].

Chapter Three examined the SNPs whish have been reported to be associated with AD. It
is well known that the ε4 allele of APOE is the major genetic risk factor for late onset of
AD. There are three apoE isoforms, apoE2 (cys112, cys158), apoE3 (cys112, arg158),
and apoE4 (arg112, arg158), determined by two SNPs rs429358 (T/C) and rs7412 (C/T),
both of which are missense variants. These isoforms have different effects on Aβ
metabolism. The binding ability of the apoE isoforms to Aβ follows the increasing order
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of apoE2, apoE3 and apoE4, and thus apoE2 and apoE3 inhibit the aggregation and
enhance the clearance of Aβ compared to apoE4 [33]. A series of genome-wide
association studies (GWAS) have identified AD-associated SNPs in addition to the
APOE alleles. Although GWAS have succeeded in revealing numerous susceptibility
variants for AD, we have relatively little understanding of the functional impact of these
loci in regards to AD pathogenesis. To understand disease development mechanisms that
genetic variants are associated with, identifying functional genes and/or variants is an
important challenge.

In this study, the possible functional effects of the IGAP SNPs on AD were examined
under two hypotheses: “the IGAP SNP is a proxy of a coding SNP” and “the IGAP SNP
is a regulatory SNP”. For the first hypothesis, rs2296160 in CR1, rs9270303, rs1049092,
and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982 in CLU,
rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 may be proxies of coding
SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in CELF1, and
rs8093731 in DSG2 may be regulatory SNPs affecting AD-associated gene expression.
Investigating the functional role of the suspected and replicated SNPs associated with AD
is an important next step to understanding the genetic contributions and the functional
pathways linking AD developmental mechanisms. AD is a complex disease with a strong
genetic component. However, much of the genetic contribution to AD remains
unexplained. In future studies, more investigations are needed to investigate how RNA
and protein levels as well as their interactions are affected by known AD-correlated
genes.
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Chapter Four presented rare variants associated with AD. Rare variants have become a
focus in the recent past. Imputed rare variants are typically removed from GWAS
analyses because of low accuracy of imputation. Recent advances in sequencing
technologies enable to accurately genotype rare variants. Whole-exome sequencing
(WES) and whole-genome sequencing (WGS) are ideal approaches to identify novel
variants and genes associated with complex traits. However, traditional single-variantbased association tests are underpowered to detect rare variant associations unless sample
size and/or effect size is very large [62]. Instead of testing single variant individually,
more powerful and computationally efficient approaches for aggregating the effects of
rare variants have become a standard approach for association testing. In this study, we
applied a scan-statistic-based approach and developed an approach to construct optimized
windows within a gene to find meaningful clusters harboring risk or protective rare
variants for AD based on the assumption that variants located in close proximity within a
functional protein-coding domain play a similar role in increased or decreased disease
susceptibility. We used TREM2 and TOMM40 as highly-replicated positive controls to
evaluate the scan-statistic-based analysis with a sliding window and an optimized
window approach. In addition to these positive control genes, we applied the optimized
window approach in all genes to identify regions that harbor AD associated loci.

We obtained very similar scan statistics when we specified the whole genome and
chromosome as a large genetic region 𝐺. This may indicate that the scan statistics are
comparable between windows in different large genetic regions if the 𝐺 is large enough.
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Ideally, it would be the best that an optimized window covers an entire gene if the gene
itself affects a disease and captures one single variant if only the variant within the gene
is significant. Our optimized window approach successfully identified the gene and the
single variant in TREM2 and TOMM40, respectively. Applying the optimized window
approach across the genome, we identified several candidate genes exhibiting risk for AD
and others playing a protective role using the optimized window approach.

Strengths and Limitations
A major strength of this dissertation is that we evaluated genetic associations of both
common and rare variants with neurodegenerative diseases using several statistical
methods. Single-variant-based association tests such as through conventional logistic and
linear regression are powerful and useful tools to identify associated common variants
having marginal significant effects on disease. Unlike Mendelian disease, however,
complex disease is not explained by a single variant in a single gene. As a functional unit,
a gene/region contains one or more significant SNPs that jointly affect a disease.
Therefore, gene/region-based association analysis is an effective strategy to identify
candidate genes/regions contributing to natural variation in a disease, as it combines
signals from all SNPs within a putative gene/region. Haplotype analysis is also another
informative approach to handle multiple SNPs. It accounts for not only heterogeneity but
also possible statistical interactions among SNPs.

There are some limitations. First, all data used in three studies come from multiple
research centers. Since a large number of observations are required in genetic studies to
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boost statistical power and to obtain more accurate estimates, collaborative groups
combine the raw individual data from each study and jointly analyze the pooled data
(referred to as mega-analysis). In mega-analysis, a concern about “heterogeneity among
studies” of the same trait has been raised. Sources of heterogeneity among studies
contains different study designs, trait measurements, ethnic groups, genotyping chips, and
so on. The statistical methods applied in this dissertation did not take into account
heterogeneity among studies. Second, dementia diagnoses vary across calendar time and
research centers. In addition, the accuracy of clinical diagnosis of AD may be hampered
by difficulty in differentiating AD from other type of dementia or AD mixed with other
neuropathological conditions [16]. Third, we aggregated data from some resources that
aid in establishing a confluence within a systems genetics framework. These datasets are
heterogeneous and can exhibit biases from the respective study designs, analytic
protocols, and participant pools. Last, we used WES to identify novel rare variants
associated with AD in the third study. Although WES is a powerful approach for
discovering mutations in coding regions, it is difficult or impossible to detect important
elements including variants in non-coding regions, large indels and repeat expansions,
and exon- or gene-level copy number variations. Therefore, WGS is better than WES to
capture comprehensive genomic associations.

Future Research
There are several future research ideas suggested by these dissertation studies. First, we
incorporated only common SNPs into the gene-based and haplotype-based analyses in the
first study. Although we showed that the associated haplotype with HS-Aging was also
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associated with the ABCC9 expression, it is still possible that the common SNPassociation signals come from a synthetic association, i.e., that detectable common SNPs
reflect the net effect of multiple functional rare variants on a disease. The synthetic
association hypothesis would suggest that confirmation studies for known SNPs should
encompass a larger region surrounding the detected common SNP in which possible rare
variants creating the synthetic association are contained. Second, we need to evaluate
impacts of allele specific expression on biological function related to AD. We excluded
monoallelically expressed genes including genes on chromosomes X and Y, and HLAgenes in the second study. However, allele specific expression is widely spread across the
genome, and have important implications in the genotype-phenotype associations [188].
Given epigenetic association between DNA methylation in HLA-DRB5 and AD
pathology [142], we will require more investigations for the association between allele
specific expression of HLA-DRB5 and AD pathogenesis. Third, the scan-statistic-based
analysis we used in the third study is performed under the important assumption that each
risk is independent because it is based on Bernoulli model. That is, the scan-statisticbased analysis does not take into account LD. If multiple associated variants are in LD,
using all of them would artificially inflate the test statistic. Therefore, we need to modify
it as considering LD structure. In addition, we could expand the scan-statistic-based
analysis for a continuous outcome using a normal distribution model so that biomarkers
related to AD development would be handled.
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